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The European Radiation Dosimetry Group, EURADOS, established a working group consisting of experts whose aim is to
assist in the process of harmonisation of individual monitoring as part of the protection of occupationally exposed workers. A
catalogue of facilities and internal dosimetric techniques related to individual monitoring in Europe has been completed as a
result of this EURADOS study. A questionnaire was sent in 2002 to services requesting information on various topics
including type of exposures, techniques used for direct and indirect measurements including calibration and sensitivity data
and the methods employed for the assessment of internal doses. Information relating to Quality Control procedures for direct
and indirect measurements, Quality Assurance Programmes in the facilities and legal requirements for ‘approved dosimetric
services’ were also considered. A total of 71 completed questionnaires were returned by internal dosimetry facilities in 26
countries. This results in an overview of the actual status of the processes used in internal exposure estimation in Europe. In
many ways harmonisation is a reality in internal dose assessments, especially when taking into account the measurements of
the activity retained or excreted from the body. However, a future study detailing the estimation of minimum detectable
activity in the laboratories is highly recommended. Points to focus on in future harmonisation activities are as follows: the
process of calculation of doses from measured activity, establishment of guidelines, similar dosimetric tools and application of
the same ICRP recommendations. This would lead to a better and more harmonised approach to the estimation of internal
exposures in all European facilities.
INTRODUCTION
Once EURATOM 96/29 Directive(1) has been imple-
mented in many European states, coordination of
the monitoring procedures of occupational workers
becomes an important matter to deal with in a con-
tinent without borders and with free movement of
workers exposed to radiation in the nuclear facilities
of different countries. The aim of the European
Radiation Dosimetry (EURADOS) working group
on harmonisation of individual monitoring is to
promote harmonisation in the field of individual
monitoring of occupational exposures throughout
Europe(2). A sub-group was formed by experts
involved in tasks related to the assessment of doses
in either internal or external exposures; the objective
to achieve was the integration of dosimetric meth-
ods, investigating how the results from personal
dosemeters for external radiation and workplace
monitoring and from monitoring for internal expo-
sure can be combined into a complete and consistent
system of individual monitoring. An important
aspect of the study is to investigate how these differ-
ent methods can be harmonised so that the numer-
ical dose values can be added to result in a total
effective dose for the worker.
In contrast to the measurements of dose for
external radiation, internal doses cannot be meas-
ured directly: they must be inferred from the
measurement of quantities such as body activity
content, excretion rates or airborne concentrations
of radioactive materials. Furthermore, the asses-
sment of exposures due to intake depends critic-
ally upon knowledge of the biokinetics of the
radionuclides.
Quality assurance in internal dosimetry is also a
complex matter; the uncertainty in the measuring
process (whole-body counting and bioassay) and in
the assumptions often made in order to establish
circumstances of the intake result in large uncer-
tainties associated to the estimated radiation dose.
There is a considerable concern within regulatory
bodies and approved internal dosimetric services
about the need for harmonisation on the evalua-
tion of internal exposures. In this way, national and
international intercomparisons have been organ-
ised for the purpose of checking not only the per-
formance of in vivo and in vitro laboratories but
also the methodology used by services to assess the
effective doses taking into account ICRP recom-
mendations and national regulations. The objective
is always to validate measurement procedures and
dosimetric tools to guarantee the reliability of
calculated doses.Corresponding author: ma.lopez@ciemat.es
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CATALOGUE OF INTERNAL DOSIMETRIC
SERVICES IN EUROPE
One of the aims of the EURADOS harmonisation
study is the completion of a catalogue of Internal
Dosimetric Services and an inventory of methods
and techniques used for individual monitoring at
the internal dosimetry facilities in the whole of
Europe. With the collaboration of a contact-person
in each country the ‘Eurados 2002 Questionnaire (2)
for a catalogue of Internal Dosimetry Techniques
used for individual monitoring in European coun-
tries’ was sent in spring 2002 by e-mail. The informa-
tion requested (Figure 1) related to various topics:
the equipment used for the measurement of internal
exposures, calibration and Minimum Detectable
Activity (MDA) data, the methods applied for the
assessment of internal doses, quality control proce-
dures for direct and indirect measurements, quality
assurance programmes in the facilities and legal
requirements for being an approved dosimetric
service. The statistical information received for
each section of the questionnaire gives an overview
of the situation of internal dosimetry in Europe
in 2001.
The contact-person in each European state was
asked to decide the appropriate laboratories to
which the questionnaire should be sent, taking into
account not only approved internal dosimetric ser-
vices but also other facilities that perform direct/
indirect measurements or dose assessments related
to internal exposures of workers. In some countries,
the responsibility for carrying out internal dose
assessments lies with a qualified expert who
may not be responsible for undertaking the
measurements.
The ‘Eurados Database of European Dosimetric
Data’ (Appendix) has been generated as a result of
this project. It contains all the information collected
from the questionnaires obtained from 114 facilities
involved in dose assessments for internal and exter-
nal exposures in 28 European states (Table AP1).
The database includes a general information section
where each country is registered with the complete
list of dosimetric services. The database will be
periodically updated, in an effort to improve the
amount of information collected and to reflect the
actual situation of the dosimetry in Europe.
A European dosimetric network of contact-
persons collaborating with EURADOS for harmon-
isation has been established. The final results
obtained from the data analysis of the Internal Dosi-
metry questionnaires (Q2), are presented here.
Information about individual monitoring of
workers at risk to intake of radionuclides in
European countries was collected by working
group 2. A total of 71 completed questionnaires
from 26 countries were received and provided a
very useful set of data covering different aspects of
the methodology required in the assessment of inter-
nal doses. A total of 58 laboratories involved in
direct measurements supplied detailed information
relating to in vivo techniques and procedures; 43
facilities working in indirect measurements of inter-
nal exposures forwarded information relating to
services using in vitro methods and personal air
sampler/static air sampler (PAS/SAS) monitoring
for the evaluation of individual doses. The countries
and number of services collaborating with Eurados
in this task are shown in Table 1.
Although no information was collected from
France, Finland or Latvia (no answers were received
Figure 1. Index of EURADOS 2002 Questionnaire (Q2) for a catalogue of internal dosimetric techniques used for
individual monitoring in European countries.
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from services in these countries), the set of 73 labora-
tories involved in internal dosimetry matters (Annex,
Table AN1) is representative of the type of expos-
ures, techniques, performance criteria and regula-
tions associated with different procedures and
monitoring programmes used by internal dosimetric
services. An important goal achieved as a result of
this Eurados Action is the availability of data from
facilities in 26 countries, including western, central
and eastern Europe working together to reach har-
monisation, taking into account the different cul-
tures and accessible tools that apply in each case
for intake determinations.
The answers of Eurados Q2 Questionnaire pro-
vided, in first instance some general information
relating to each internal dosimetric service (name
and complete address, and person in charge of the
service) thus facilitating contact with those services
in a quick and easy fashion. Table 1 gives an indica-
tion of the number of services that replied against the
number in each country. The Eurados catalogue
along with the European databases give a reason-
able overview of the status of internal dosimetry
in Europe.
TYPE OF INTERNAL EXPOSURES OF
EUROPEAN WORKERS
Internal monitoring programmes designed by ser-
vices were investigated to ascertain the type of occu-
pational exposures received by monitored workers in
Europe (Figure 2). The majority of workers moni-
tored for internal exposures work in nuclear power
plants (NPPs), research activities and the medical
field. Non-nuclear industry, the nuclear fuel cycle
Table 1. Countries and internal dosimetric services
collaborating with Eurados 2001.
Code Country ID Services
Eurados
ID Services
Total
AT Austria 2 5
BE Belgium 1 1
BG Bulgaria 1 3
CH Switzerland 7 7
CS Serbia and
Montenegro
2 2
CZ Czech Republic 4 4
DE Germany 8 25
DK Denmark 1 1
EE Estonia 1 1
ES Spain 9 10
GB United Kingdom 3 10
GR Greece 2 2
HR Croatia 1 1
HU Hungary 2 4
IE Ireland 1 1
IT Italy 8 18
LT Lithuania 2 2
NL Netherlands 1 1
NO Norway 1 1
PL Poland 1 1
PT Portugal 1 1
RO Romania 5 5
SE Sweden 3 7
SI Slovenia 3 3
SK Slovakia 2 2
UA Ukraine 1 1
Total 73 119
Internal dosimetric services that answered Eurados Q2
questionnaire per country
Total number of internal dosimetric services in each
country
Figure 2. Type of internal exposures associated with the individual monitoring of European workers.
INDIVIDUAL MONITORING FOR INTERNAL EXPOSURE IN EUROPE
71
and decommissioning activities are other workplaces
where the intake of radionuclides must be evaluated.
In 2001 monitoring of workers involved in depleted
uranium incidents was also dealt with by some
services.
Table 2 gives an overview of the monitored work-
ers and number of measurements performed in 2001
in the 73 laboratories from 26 countries that have
collaborated with Eurados in this harmonisation
study. The results show that there are more workers
included in individual monitoring programmes to
assess internal exposures with direct techniques
(in vivo detection of X-ray and gamma emitters in
whole-body counting or organ counting), compared
with the number of persons controlled by indirect
procedures (Bioassay and PAS/SAS monitoring). In
contrast, as it was expected, the number of in vitro
measurements (assessment of activity of alpha, beta
and gamma emitters in excreta samples) together
with PAS/SAS monitoring for the assessment of
individual doses, is higher than the number of
in vivo evaluations. This fact is explained by the
requirement of more frequent routine monitoring
programmes for the annual determination of alpha
and beta emitters using indirect techniques, taking
into account parameters such as sensitivity of equip-
ments and dose levels to detect, following regula-
tions in force.
TECHNIQUES AND PERFORMANCE
CRITERIA FOR THE EVALUATION OF
INTERNAL EXPOSURES
Direct techniques
Direct measurements of the radiation emitted by the
internally deposited radionuclides are suitable for
those isotopes which emit photons of sufficient
energy and in sufficient numbers to escape from the
body and be measured by an external detector. X-ray
and gamma emitters (and to a lesser extent high-
energy beta emitters) can be evaluated by direct
external measurements using a whole-body counter
(WBC) or organ counter, with an easy identification
but a not-so-easy quantification of radionuclides,
based on the emitted energy spectra.
In vivo detection offers the advantage of a rapid
estimate of activity in the whole body or in an organ
of the body at the time of the measurement. The
direct techniques are characterised, in the first
instance, by spectrometry features such as resolu-
tion, efficiency and sensitivity; other factors to take
into account are the counting geometry, the control
of the background, the calibration method, uncer-
tainties associated with assessments and quality
assurance. The objective is to guarantee the capabil-
ity of in vivo techniques to detect and to evaluate the
intakes of the radionuclides of interest.
The Eurados study for the harmonisation of indi-
vidual monitoring represents an important source
of information which indicates the status of direct
determinations of internal contaminations in
Europe. The collected information gives an overview
of the type and characteristics of in vivo detection
systems used by the laboratories, the materials and
dimensions of shielding rooms, the counting geome-
tries applied, calibration phantoms and methods,
procedures for assessment of activities (software,
counting time, detection efficiency) and the MDAs
(sensitivity of the in vivo detection systems) of more
relevant radionuclides in each geometry.
Figure 3 shows the analysis of the Eurados data
relating to direct techniques. The main type of meas-
urements used for individual monitoring of internal
exposures are whole-body counting (in vivo detection
of gamma emitters 100–3000 keV in total-body),
thyroid counting (assessment of 125I and 131I) and
monitoring of actinides in lungs. Other types of
in vivo detection have been implemented in some
facilities: determination of actinides in bone or
liver, in vivo detection of beta emitters, assessment
of contaminants in wound or hand counting. The
selection of the appropriate technique for individual
monitoring must take into account the type of occu-
pational exposure and the actual risk of intake of
specific radionuclides at the workplace.
As expected whole-body counting, thyroid moni-
toring and lung counting are commonly used for
in vivo measurements, reflecting the type of workers
controlled for intake of radionuclides.
Whole-body counting
The determination of gamma emitters in a whole-
body counting geometry is most frequently used by
the participants of this study. Technical information
was obtained on approximately 62 WBCs from 52
European laboratories, providing an overview of the
status of direct determination of fission and activa-
tion products in the body and other radionuclides in
the range 100–3000 keV.
The group of WBCs counters considered in this
study includes 5 mobile units, 30 detection systems
inside shielded rooms and 28 equipments with no
Table 2. Exposed workers monitored in 71 internal
dosimetric services of 26 European countries (status 2001).
Assessment of
internal exposures
Monitored
workers
Measurements
performed
Direct methods
(WBC, organ counting)
31,800 63,400
Indirect techniques
(Bioassay, PAS/SAS)
12,700 67,500
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shielding room. After the Chernobyl accident,
mobile units became an important direct technique
to be used in the case of radiological accidents as
well as in routine monitoring. The data collected
from this sample of European facilities is illustrative
of the different procedures and available methods
related to the in vivo determination of gamma emit-
ters in total-body.
Shielding room. The interest of performing direct
measurement using detectors inside a shielded room
is the background reduction, mainly with the objective
of decreasing the limits of detection, to reduce count-
ing time, to minimise the uncertainty associated with
the measurement (counting statistic and variation of
background), and to moderate peaks that can cause
interference during the analysis of spectra. The back-
ground in the energy range of interest (10–3000 keV)
arises from several sources: environmental back-
ground, radionuclides in the body and background
generated by shielding, equipment and detector
materials. Without shielding, the cosmic radiation
contributes in the spectrum in the form of a conti-
nuum with very few photopeaks, but other
photopeaks originating from natural radioactivity
are also present. With effective shielding, the
background component that is more significant is
the radionuclides within the shielded enclosure.
ICRU 69(3) establishes that a counting room
(2.25  1.5  1.80 m3) consisting of 15 cm thick
steel, and with an inner graded lining of 4 mm of
Pb, 3 mm of Sn and 0.4 mm Cu provides a measured
attenuation factor for external gamma radiation of
100 in the energy range for transmitted photons of
150–2000 keV. Steel is the recommended material for
the outer shield of a counting room and lead is the
more convenient material for the inner shield; cad-
mium can be used as an alternative to tin and iron is
sometimes an alternative to copper.
As already stated, 30 of the 62 WBCs included in
the Eurados study are operative in a shielded room.
Most of the facilities (23 WBC) use steel for the outer
shield, with the thickness of walls varying from 10 to
21 cm, and an average value of 16 cm of steel for the
counting room; other laboratories prefer concrete
(70 or 30 cm) or iron (8 or 15 cm). Lead is the
more common material used as inner shield, with
thickness varying from 1 to 10 mm, the general
choice being 3 or 5 mm of Pb; the other elements
used as graded-lining are Cu and Cd.
Counting geometry for whole-body counting. The
counting geometry selected by an in vivo facility for
direct measurements takes into account the physical
characteristics and biokinetic behaviour of the
radionuclides to be detected, the application of
measured results and available space and resources.
The main application of the laboratories included in
this harmonisation study is individual monitoring
and evaluation of internal doses for radiation
protection purposes; the objective to achieve is to
perform measurements with a configuration that
makes maximum efficiency and sensitivity available.
Different detector–subject arrangements are pos-
sible in the case of total-body determination of
gamma emitters; the most common counting geome-
tries place the person on a bed or in a special chair.
The analysis of the resulting spectrum will provide
Figure 3. Type of direct techniques applied for the individual monitoring of European workers.
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the activity of radionuclides detected in the whole
body, assuming homogeneously distribution of
radioisotopes. In the case of total-body single-
detector measurements, the recommended (ICRU
69) types of monitoring are chair geometry, arc geo-
metry and bed or stretcher geometry (stationary or
scanning). If the in vivo system is a multidetector,
the recommended counting geometries are station-
ary stretcher geometry, stationary arc geometry and
line scanning stretcher geometry. With reference to
quick body monitoring, a vertical array of detectors
is used in some cases, with the subject standing up
for a short time; this represents a quick, screening
technique rather than an in vivo method for quanti-
tative measurements that requires high accuracy.
Analyses of the configurations used in the 62
WBC performing total-body evaluations of gamma
emitters show that not only bed or chair geometries,
but also the standing-up position are employed
(Table 3). Bed geometry seems to be the most widely
used configuration for the whole-body determina-
tion of high-energy gamma emitters, with almost
half of the facilities preferring it; 14 laboratories
utilise scanning or moving-bed arrangements, and
2 the stretcher geometry.
Whole-body counting detector system. NaI(Tl) or
Ge detectors are the counting systems commonly
used for whole-body counting. The selection of a
detector for in vivo measurements depends upon its
application. The radionuclides to be detected,
features of the detector (resolution, intrinsic
efficiency, stability), background response and cost
are factors that must be considered. For high-energy
photons, thick detectors are typically used to opti-
mise the probability of a photoelectric interaction in
the detector.
A majority (53%) of the European laboratories
who participated in the Eurados project use
NaI(Tl) detectors for in vivo total-body monitoring
of radionuclides. A total of 15 facilities have single-
detectors systems, 8 facilities use 2-detectors systems
and 10 WBC use an array of 4 NaI(Tl) detectors
(Table 4).
A large number, 21 facilities, have instal-
led high purity germanium (HPGe) detectors, with
13 laboratories selecting single-detector systems and
8 WBC installing multidetectors systems with differ-
ent arrays: 2-detectors, 3-detectors, 4-detectors and
6-detectors (Table 5). The remaining four in vivo
facilities (Table 6) perform their measurements
using both scintillation detectors (NaI(Tl)) and
semiconductor detectors (HPGe).
Whole-body counting calibration phantoms. An
important matter of interest is the calibration
procedure of the detection systems for the assess-
ment of the activity of gamma emitters (E >
200 keV) deposited in total-body. The methods and
tools used by the 62 WBC facilities collected in the
Eurados harmonisation study have been analysed.
In vivo calibration requires phantoms as human
simulators with assumed radionuclide distributions.
Phantoms must be anthropometric (same measure-
ment characteristics as a human), but in the case of
high-energy photon emitters, they do not have to be
anthropomorphic (Table 7). The calibration phan-
toms recommended for the direct measurement of
internal exposures are described in ICRU 48(4).
The bottle phantom, the brick phantom fabricated
by the Research Institute of St Petersbourg during
the last 10 y with active rods containing isotopes for
calibration, and the BOMAB phantom consisting
of 10 pieces of polyethylene simulating the ICRP
standard man with the set of radionuclides homo-
geneously distributed in the phantom are the pre-
ferred phantoms in facilities with WBC for the
calibration of NaI(Tl) and HPGe detectors. Other
types available are the torso phantom and the RMC
transfer phantom. The massonite phantom has been
selected in some Spanish WBCs, but they are in the
process of changing to the BOMAB phantom for
calibration purposes.
The phantoms used for the calibration of in vivo
detection systems must simulate the behaviour and
interaction of the ionising radiations in the body.
Phantoms should be constructed with materials
that provide equivalent photon transmission proper-
ties of the different human tissues. The attenuation
properties of water are very close to soft tissue and,
along with special plastic materials to contain the
water, an anthropometric phantom can be con-
structed. Most WBCs are calibrated with phantoms
consisting of plastic containers filled with standard-
ised radioactive water-based solutions (bottle phan-
toms and BOMAB phantoms constructed with
polyethylene cylinders).
Whole-body counting calibration source. 137Cs
and 60Co are the elements more commonly employed
by European in vivo facilities for calibration purposes.
Laboratories prefer a mixture of radionuclides for
calibration, where 152Eu and 133Ba seem to be widely
Table 3. Counting geometries applied in WBC for the
evaluation of gamma emitters in total body.
Whole-body counting No. of WBC
Bed geometry 29
Chair geometry 15
Standing-up geometry 10
Arc geometry 1
Simple Box geometry 1
M. A. LOPEZ PONTE ET AL.
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used due to their multiline emissions. Mixed nuclide
sources commonly prepared also contain 109Cd,
139Ce, 203Hg, 113Sn and 88Y; with other radionuclides
as 134Cs, 141Ce, 85Sr, 65Zn, 54Mn or 235U being used
in a few instances.
The calibration of WBCs is performed with a
radiation source that emits photons with energies
covering the operative range of the detection system.
In order to obtain a good fit in the calibration
efficiency curve, particularly the low-energy contri-
bution, 57Co and 241Am are the preferred radionu-
clides, due to their very-low-energy gamma
emissions.
Fifteen per cent of the WBCs included in the
Eurados study decided to perform the total-body
calibration of the in vivo system with 40K in the
source (applying to both scintillators and semicon-
ductors). This is important to note, especially in the
case of calibration for the 60Co evaluation with
NaI(Tl) detectors (interference of 40K body
emissions).
MDA for whole-body counting. Eurados Q2
questionnaire contained a section dedicated to the
assessment of Minimum Detectable Activity (MDA)
for 137Cs and 60Co, as an indicator of the sensitivity
of the in vivo detection system in whole-body count-
ing geometry; information of counting time, effi-
ciency and the blank used for MDA estimation
(Table 8) was collected from the 62 WBC.
Counting times, in routine whole-body counting,
are spread out over a very wide range, 60–3600 s. A
total of 13 WBC utilise a time of 600 s, with a further
13 facilities using 1000–1200 s. Finally, for quick
counting, 60–70 or 120 s are the options selected.
Table 4 shows some selected data related to the
MDA in force in facilities using NaI(Tl) detectors
for the in vivo detection of gamma emitters in total-
body. Table 5 presents the more relevant data
associated to the laboratories operating with semi-
conductors (HPGe) for the direct determination of
radionuclides in whole-body; MDA values in Bq for
137Cs and 60Co are also given. Table 6 shows the
data of four facilities operating with a mixture of
detectors (NaI(Tl) and HPGe) for whole-body
counting evaluations; MDA values are also
presented.
The sensitivity of the detector system has been
given for 137Cs and 60Co where the MDA represents
the detection limit of the system expressed in terms
of the activity. For in vivo equipment in a whole-
body application, a specific blank is used to obtain
background counts. The MDA is calculated here
using as background a measured blank person or a
phantom simulating the human body and containing
an expected amount of 40K. The Eurados study does
not take into account how facilities obtain the MDA
data (ISO, ANSI, NUREG, etc.). Facilities were
required to supply information relating to the
Table 6. MDA of European facilities using NaIþHPGe for whole-body counting determinations.
Ref. Shield
room
Geometry
description
Detector
system
Calibration
phantom
Blank Tc (s) MDA
137Cs (Bq)
MDA
60Co (Bq)
Bg-KO Yes Moving bed and vertical
moving detector
1 NaI(Tl)þ
3 HPGe
Polythene modules Person 600 326 340
Gr-GA No Moving bed geometry 1 NaI(Tl)þ
1 HPGe
RMC-II phantom,
Bottle phantom
Empty
bed
1460 30
Se-OK Yes Chair geometry 2 HPGeþ
1 NaI(Tl)
Solid tissue
equivalent phantom
Phantom 600 31 38
Ua-RM Yes Six detectors in line along
human body under bed
1 NaI(Tl) þ
1 HPGe
Human body
tissue shape filled
split peas
Phantom 600 24 28
Table 7. Calibration phantoms used for the WBC
evaluations in European in vivo facilities.
Calibration phantoms
whole-body counting
No. of WBC
Bottle phantom 14
BOMAB phantom 13
Brick phantom 12
RMC phantom 7
Torso phantom 5
Massonite phantom 10
Others 4
Table 8. Type of blank used for MDA calculations in whole-
body measurements.
Person Phantomþ
40K
Phantom Background
No. of
facilities
19 14 15 3
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parameters that affect the sensitivity of the system
(type and number of detectors, shielding, counting
geometry, efficiency, type of blank and counting
time) together with the MDA values for 137Cs and
60Co, in order to compare the data. It is worth not-
ing here the publication ICRU 69, contains a
comparison of MDAs achieved by different WBCs
(NaI(Tl) and HPGe).
It was quite difficult to extrapolate strong conclu-
sions from the comparison of MDA values reported
by laboratories collaborating with Eurados in the
harmonisation project. The information collected
was separated into different groups depending on
the type of detectors (Tables 4–6) and parameters
such as counting time, number of detectors, type of
blank as well as the counting geometry used in each
case. It was found that similar sets of these para-
meters corresponded to different MDA values,
thereby leading to the conclusion that there is a
need for harmonisation in methods and procedures.
This finding is especially applicable to HPGe detec-
tors where it was expected that under similar mea-
surement conditions longer counting times resulted
in lower MDA. However, this was not the finding in
the Eurados study (Table 5).
Considering the percentages of the number of
occurrences of a given value of MDA in a specific
interval over the total number of available values,
some information can be drawn regarding the spread
of the collected MDA values. Figure 4 shows the
percentage values that have been reported. A
100 Bq interval has been chosen for both radionu-
clides up to 1000 Bq. As can be seen, results related
to NaI(Tl) WBC types are more widely distributed
than those related to HPGe. Approximately 60% of
the MDA values for HPGe WBC are present in the
first MDA interval (0,100) Bq, for both radionu-
clides as compared with 40% of those related to
NaI(Tl) types. The higher MDA values are only
associated with NaI(Tl) type WBC (values >500
Bq). For the HPGe type WBC the distribution of
occurrences is narrow for 60Co in respect to 137Cs.
The lowest MDA reported was 3 Bq of 137Cs and
7 Bq of 60Co of a WBC using 1 NaI(Tl) detector
(200 mm diameter, 100 mm thickness) in a shielding
room (steel walls with wood, Pb and brass); the
tilted chair geometry was applied, for a counting
time of 2000 s. Calibration was undertaken with a
BOMAB phantom, using a Blank with 40K for
MDA calculations.
The optimisation of MDA values seems to be
achieved using a mixture of detectors, NaI(Tl) and
HPGe, in shielding room using a bed geometry. Two
countries reported that they used this configuration,
with a counting time of 600 s, obtaining MDA values
of 20–30 Bq for 137Cs and 60Co, respectively. Good
results are also reported for 4 WBCs using NaI(Tl)
detectors and a counting time of 1200 s, agreeing in
values of 60–70 Bq for 137Cs for and 50-60 Bq
for 60Co, obtained with different sets of calibration/
counting data. Quick counters using NaI(Tl) detec-
tors, with a measurement time of 60 s reported MDA
values in the range of 100–250 Bq for 137Cs and 60Co.
As was expected, in general, the use of HPGe
detectors requires longer counting times to achieve
the same MDA values as using NaI(Tl) detectors.
Seventy-five per cent of the in vivo facilities using
semiconductor detection systems selected counting
times in the range of 600–1200 s. Three laboratories
using HPGe detectors and a measurement time of
1200s reported quite similar MDAs to the NaI(Tl)
values. One facility using 1 HPGe detector in a
Figure 4. Percentage of occurrences in a given MDA interval (WBC measurements).
INDIVIDUAL MONITORING FOR INTERNAL EXPOSURE IN EUROPE
79
shielding room, employing a chair geometry and
obtaining 100 and 80 Bq for MDA values have the
measurement time of 3600 s. As a final conclusion
for HPGe detector system used for whole-body
determinations, it is worth noting that there is a
lack of agreement in the results of MDA in that
similar sets of parameters resulted in different
MDA values. It is recommended that this be further
studied with a more detailed investigation of MDA
calculations of European in vivo facilities.
Thyroid counting
Other types of in vivo measurement counting are
required when considering intakes of radionuclides
that are deposited in some particular organs. This
happens, for example, when internal exposures to
radioiodine occurs and it is retained in the thyroid
gland. Counting geometry for thyroid monitoring
consists of one or more detectors of a suitable size
placed close to the surface of the neck over the
thyroid area, with the subject either in a supine or
sitting position. A collimator or shield is recom-
mended to minimise interference from radionuclides
in other parts of the body.
The Eurados harmonisation study includes
44 thyroid counters at some 38 in vivo facilities.
This represents an illustrative sample of thyroid
monitoring in Europe with the information collected
showing that both, NaI(Tl) and HPGe detectors are
used for the evaluation of the activity of 131I and 125I
deposited in thyroid. 131I is a gamma emitter with an
easily identifiable spectrum and characteristic photo-
peak of 364.5 keV; the assessment of 125I can be done
from the analysis of the X-ray typical emissions
27.1 keV and/or using the low-energy gamma
photopeak of 35.5 keV.
Calibration for thyroid monitoring requires a spe-
cial phantom that simulates the size and shape of this
organ, and which must be realistic in the attenuation
of the overlying tissue-equivalent material. A variety
of phantoms are reported in ICRU 69 publication by
Kramer et al.(5).
In vivo assessment of 131I in thyroid. The most
frequently used measurement system for the in vivo
determination of 131I in thyroid is one NaI(Tl) detector
(Table 9). A few services have installed one HPGe
detector or multidetector systems. All the determina-
tions are carried out from the analysis of the 364.5
keV photopeak in the gamma spectrum. A thyroid
detector distance of 10–15 cm is used in 50% of the in
vivo counters. The remainder are divided into those
that apply close distances of 1–5 cm, and a small
number who prefer long distances of 20–30 cm.
With reference to calibration phantoms a
great variety are chosen, as shown in Table 9. The
assessment of the activity of 131I in the thyroid is
carried for counting times varying from 10 to 1800 s
with 500–600 s being typical in 16 of the 42 respond-
ents. The MDA is obtained from the measurement on
a blank phantom (50% of the laboratories performing
thyroid monitoring) or a blank person. In both cases
MDAs in the range 4–800 Bq of 131I in thyroid are
achieved. Three facilities using one HPGe detector at
close distances (10 cm) for counting times of 600–
1000 s reported the lowest value of MDA, 5 Bq of
131I in thyroid. A future study of the harmonisation of
MDA is also recommended, which considers more
fully the procedure for calculating the limit of detec-
tion for 131I in thyroid monitoring in European in vivo
laboratories.
In vivo assessment of 125I in thyroid. Table 10
shows selected data related to the direct measure-
ment of 125I in the thyroid in 13 European in vivo
facilities. The X rays (27 keV) and very-low gamma
detection (35 keV) is carried out using semiconduc-
tors (HPGe and LEGe) detection systems (six
laboratories) and also scintillators (NaI(Tl)). The
detection device is placed over the neck, close to
the thyroid area, with thyroid-detector distances
ranging from 2 to 15 cm. The most frequently used
distances are found to be 10–15 cm. The lowest
MDAs reported correspond to 2–6 Bq of 125I in the
thyroid, where the detection of 27 keV emission by
germanium detectors and one Na(Tl) detector is
recorded and different counting times (300, 600 and
1200 s) are used.
As with the comparison for MDA values in
WBC measurements, a comparison of the percen-
tages of the number of occurrences of a given
value of MDA in a specific interval over the total
number of available values can provide some
indication of the spread of the data collected. In
Figure 5 those values are reported for the two
monitored radioisotopes.
Figure 5 shows the distribution of MDA values
for the two radioisotopes are very similar. In the case
of 125I, due to the small number of data, one value at
360 Bq represents 10% of the distribution. In the case
of 131I one-third (31%) of the distribution of values
is >160 Bq.
Lung counting
Lung counting is the type of in vivo measurement
recommended for radionuclides with long residence
times in the lung, such as uranium oxides, plutonium
and 241Am oxides. An optimisation study of count-
ing efficiency is required to achieve the sensitivity of
the detection system for the measurement of low-
energy photons emitters that are of interest in
occupational exposures; it has been reported that
detection efficiency is higher if the subject is
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measured in a sitting rather than a supine position as
described by Palmer(6).
A total of 12 laboratories collaborated with
Eurados in providing information related to para-
meters and methods applied in lung monitoring; a
selected data of services and procedures are pre-
sented in Tables 11 and 12. Some in vivo facilities
like French internal dosimetric services, are not
included in the study (no answers of questionnaires)
representing an important gap of information in the
overview of this type of monitoring in Europe.
In vivo measurements of radionuclides in lung
typically involve the detection of X rays and/or
photons with energies <200 keV; Phoswich detectors
(excellent detection efficiency, worse resolution com-
paring with germanium detectors) have been tradi-
tionally used to evaluate radionuclides emitting
photons in this range of energy. In case of multiple
radionuclide exposure, the excellent resolution of
germanium systems is the better recommenda-
tion. The majority of the laboratories involved in
the Eurados harmonisation study use germanium
detectors for lung monitoring; the detection systems
consist of different arrays of detectors of different
sizes. Two cases of Phoswich and another of NaI(Tl)
are presented here as an alternative technique of
semiconductors (Table 11).
Anatomically realistic phantoms should be used
for lung calibration with the detectors being located
close to the surface of the body. The differential
attenuation in muscle, adipose tissue, lung and
bone must be accurately simulated using anthropo-
metric phantoms such as the LLNL (Lawrence
Livermore National Laboratory) phantom or the
JAERI (Japanese Atomic Energy Research Institute)
phantom; all the phantoms available for lung mon-
itoring are described in ICRU Report 48 (1992).
When measuring low-energy photon emitters
(<100 keV) deposited in lungs, the thickness of the
overlying tissue (chest wall thickness or CWT)
becomes an important parameter to take into
account in the in vivo calibration (counting effi-
ciency) and in activity calculations. Therefore, cali-
bration for low-energy photon measurements in
lungs requires the use of phantoms with various
overlying tissue substitute plates. The efficiency as a
function of CWT is then evaluated by an exponential
function obtained from experimental data after the
measurements of the realistic torso phantom.
Table 12 shows those European laboratories that
use LLNL and Alderson phantoms for lung calibra-
tion. Sets of overlying chest plates of 50% muscle
and 50% fat are employed to obtain the efficiency
function depending on CWT (other facilities did not
supply this information). The assessment of the
activity of radionuclides in lungs is carried out
from in vivo measurements of 241Am, 235U,
234Th/238U, 239Pu and 232Th.
Counting times for lung monitoring vary from
1200 to 3000 s; the MDAs that have been
reported refer to a CWT of 2.5 cm for a blank
person. Some agreement seems to be achieved in
Percentages of occurrences in a given MDA interval -
Thyroid measurements
Figure 5. Percentage of occurrences in a given MDA interval (thyroid monitoring).
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Table 11. In vivo detection of radionuclides in European facilities performing lung monitoring (1).
Ref. Shielded room Detector
system
Diameter
(mm)
Thickness
(mm)
Window Geometry CWT estimation
At-AR 300 mm concrete,
10 mm steel, 40 mm lead
2 HPGe 54, 56 54, 58 Be Bed Estimate from
height and weight
Be-SC 2.25  1.5  1.8 m3;
steel, wood, Pb, Sn, Fe
2 HPGe 50 20 C-Epoxy Chair Sumerling (NRPB)
formula
Cz-NR 2.5  2.0  2.0 m3;
old steel walls 21 cm thick
2 LEGe 51 20, 15 C-Epoxy
(0.5 mm)
De-KT 4.2  2.25  2.25 m3;
150 mm Fe, 3 mm Pb,
1.5 mm Snþ 0.5 mm Cu
2 Phoswich 200 1 NaI;
50 CsI
Be (1 mm) Bed LLNL chest
phantom
De-SH 1.5  2.2  2.0 m3;
120 mm steel, 10 mm
Pb, 5 mm Cu
6 HPGe 52 20 Be
(0.5 mm)
Estimate from
height and weight
Es-CI 2.43  2.43  1.97 m3;
130 mm steel, 5 mm
Pb, 0.7 mm Cd, 0.7 mm Cu
4 LEGe 70 25 C-Epoxy Reclined
chair
Sumerling (NRPB)
formula
Gb-AW No shielded room 4 HPGe 80 25 C-Epoxy Chair Ultrasonic
measurements
Hu-AE 2.2  2.0  160 m3;
200 mm old steel, 4 mm
old Pb, 1 mm Cu
1 NaI(Tl) 150 100 Al (0.5 mm) Stretcher
Hu-RR 2.2  1.6 m2; 150 mm Fe,
2 mm Cu
2 Planar
Ge
70 30 C-Epoxy Bed
It-IS 2.7  2.2  2.4 m3; 1 NaI(Tl) 203 101.6 T. CH
It-EN 700 mm concrete,
200 mm Fe, 3 mm Pb,
2 mm Cu, 3 mm plastic
4 LEGe 76 25 C-Epoxy Stretcher
Ua-RM 2.4  2.2  2.0 m3;
wall thickness
200 mm steel
2 Phoswich 150 2 NaI;
40 CsI
Al
(0.1 mm)
Bed 2.5 cm
Table 12. In vivo detection of radionuclides in European facilities performing lung monitoring (2).
Ref. Detector
system
Calibration
Phantom
Overlay
plates
Radionuclide E (keV) Tc
(s)
Blank CWT
(cm)
MDA
(Bq)
At-AR 2 HPGe IAEA 241Am 59.5 2000 Background 26.0
238U 352 2000 Background 14.0
232Th 238 2000 Background 8.0
Be-SC 2 HPGe LLNL All 241Am 59.5 3000 Person From
1 to5
From
6 to 9
De-KT 2 Phoswich LLNL 50% muscle
50% fat
241Am 59.5 2000 Person 2.5 4.9
De-SH 6 HPGe LLNL 50% muscle 235U 185.7 2400 Person 2.4 3.8
50% fat 241Am 59.5 2400 Person 2.4 3.6
Es-CI 4 LEGe LLNL 50% muscle 241Am 59.5 2700 Person 2.6 6.8
50% fat 235U 185.7 2700 Person 2.6 3.0
234Th/238U 63.2 2700 Person 2.6 40.0
Gb-RW 241Am 59.5 8.0
Gb-AW 4 HPGe LLNL 50% muscle 235U 185.7 1800 Person 3.0 4.0
50% fat 234Th/238U 63.2 1800 Person 3.0 30.0
241Am 59.5 1800 Person 3.0 4.0
It-IS 1 NaI(Tl) Alderson 241Am 59.5 1800 Person 2.2 8.0
It-EN 4 LEGe Alderson 50% muscle 241Am 59.5 1200 Person 2.5 7.0
50% fat 239Pu 16.7 1200 Person 2.5 2200.0
234Th/238U 63.2 1200 Person 2.5 40.0
Ua-RM 2 Phoswich 241Am 59.5 1800 Person 2.5 6.0
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MDA estimation of 241Am in lungs, with values
generally lying in the range 4–8 Bq. Lowest values
of MDA correspond to in vivo determination of
3–5 Bq 235U in the lungs. An aliquot of 40–45 Bq
of 234Th is the MDA obtained by laboratories for
the assessment of 238U in the lungs, assuming
equilibrium conditions.
As conclusion of the lung monitoring study,
further investigations about how services estimate
MDA is recommended as a continuation of this
harmonisation action supported by Eurados.
Other in vivo counting (skeletal, wound and beta/
Bremsstrahlung measurements)
Some in vivo facilities confirmed their ability to per-
form other types of in vivo measurements such as the
determination of the activity in the skeleton, hand
counting and wound monitoring and in vivo beta
counting. A summary of these techniques is pre-
sented below.
In case of bone-seeking radionuclides emitting
low-energy photons (210Pb or 241Am), the in vivo
measurement of the activity deposited in bone is
usually performed in a isolated region of the body
like the skull or the knee. The assessment of total
activity retained in the skeleton is calculated from
the estimation of the fractional activity deposited in
the region viewed by the detector. Calibration phan-
toms are available for in vivo measurement of low-
energy emitters in the skull and knee.
Measurement of the radionuclides in a wound is
recommended in the case of accidental contamina-
tion, to quantify and localise the activity remaining
in the wound site. Small or collimated detectors
should be used to determine the activity distribution
in the wound.
Beta emitting radionuclides can be measured
either by Bremsstrahlung photon emission or
through direct detection of the beta particles. Only
beta emitters with high enough energy could be
detected by gamma spectrometry. Bremsstrahlung
monitors can be designed as whole-body or partial-
body counters placed above and below the body.
Phoswich detectors, thin NaI(Tl), planar HPGe
and/or HPGe in combination with plastic scintilla-
tors can also be employed. 90Sr, and its progeny 90Y,
is a typical pure-beta emitter, being suitable for
Bremsstrahlung counting. ICRU 69 establishes the
range 800–1500 Bq as lower limit of in vivo detection
of 90Sr/90Y in whole-body.
Indirect techniques
A radiochemical analytical laboratory is required for
indirect measurements on biological samples. Radio-
chemical analysis detects low levels of activity in the
samples, providing a sensitive method for the meas-
urement of internal exposures in many cases. From a
routine monitoring point of view, urine measure-
ments are normally chosen to determine the rate of
loss of radioactive material from the body; the
assessment of intake and dose is carried out by
using an adequate biokinetic model.
The quality assurance of in-vitro laboratories in
Europe is mainly coordinated by PROCORRAD
Association funded in 1995 by CEA (Commissar-
iat de l’Energie Atomique, France), ABNF (Asso-
ciation des Biologistes de l’Industrie Nucle´aire
Franc¸aise) and COGEMA (Compagnie Ge´ne´rale
des Matieres Nucle´aires). Radiotoxicological inter-
comparison exercises are carried out every year.
Other intercomparison exercises have been orga-
nised by BfS (Bundesamt fu¨r Strahlenschutz) and
IAEA.
Analytical procedures and equipment for indirect
measurements vary among bioassay laboratories.
Publication ISO12790(7) establishes the performance
criteria recommended for analytical determinations
of radioactivity burdens in biological samples;
in vitro facilities need of specific equipments and
appropriate sample preparation, to carry out chemi-
cal processing and radionuclide quantification. With
reference to the sensitivity of the techniques, for
analysis involving radiochemical separations and
radioactivity counting processes of a radionuclide
in a biological sample, the chemical recoveries and
counting efficiencies can be taken into account sepa-
rately or they may be incorporated to the calibration
factor for MDA calculations.
A total of 43 European laboratories have collabo-
rated with Eurados, supplying information about
procedures and techniques related to the analysis of
excreta for the assessment of internal exposures. The
collection of urine and faecal samples from workers
with a risk of intake of radionuclides is usually
carried out for radiation protection purposes.
Occasionally other types of samples such as breath,
nasal fluid, blood, hair or finger nails are also
analysed.
Indirect measurements performed by facilities
have also been examined (Figure 6), with the focus
being on the type of radionuclide being evaluated
(actinides, beta and gamma emitters) and the techni-
que to apply (bioassay determinations or PAS/SAS
monitoring). A total of 26 laboratories are involved
in the detection of pure-beta emitters in excreta (3H,
90Sr/90Y, 14C, etc.). Information relating to in vitro
measurements of actinides was provided by 19
laboratories, 17 European facilities of the Eurados
group perform measurements for gamma emitters
in excreta, and a small set of services is
involved in PAS/SAS monitoring. The most relevant
information received is presented in more detail
below.
M. A. LOPEZ PONTE ET AL.
86
Indirect measurements of actinides
Table 13 shows the capability of laboratories to per-
form indirect measurements for the determination of
actinides in excreta. Alpha spectrometry is the tech-
nique most commonly used by services (14 of the
19 laboratories included in the study), and the ICP/
MS measurements (a expensive technique with excel-
lent sensitivity) are available in three facilities. Alter-
native indirect determinations are carried out using
Fluorimetry, phosphorescence laser-induced or
KPA for uranium measurements, liquid scintillation
counting (LSC) (application to alpha emitters),
LABSOC and Waterscintillator, and gamma
spectrometry.
A total of 12 laboratories perform indirect evalua-
tion of actinides in both urine and faeces; six services
only do urine analysis and one facility only supplied
information for the determination of actinides in
faeces. One facility measures radionuclides in blood
and in other body tissues. Detailed information
about sample preparation and measurement proce-
dures is presented in Table 14. Reported MDAs
permit comparisons to be made with the sensitivity
of the different methods used for the evaluation of
actinides in excreta. MDAs obtained by services for
urine analysis of 24 h samples, are mostly included in
the interval 0.1–0.5 mBq d1, with the counting time
varying from 220,000 to 430,0000 s; other reported
MDA are in the range 0.1 (500,000 s)–0.5 (250,000 s)
mBq l1 of actinides in urine.
Alpha spectrometry is a sensitive technique requir-
ing a long counting time for the determination of
alpha emitters in excreta. No detailed information
has been supplied by the three facilities that perform
measurements with ICP/MS technique, although it is
known that much shorter times are necessary to
evaluate radionuclides such as 238U, 235U and 232Th
in urine.
An analysis of the data supplied by European
facilities performing indirect measurements of acti-
nides in biological samples shows harmonisation in
the technique selected for bioassay determinations,
with alpha spectrometry using passivated implanted
planar silicon (PIPS) detectors being routinely used
and in one service a silicon surface barrier. There is
also agreement among laboratories relating to the
volume of the collected sample for urine and faeces
(24 h samples), with normalisation by creatinine
content in urine in two facilities. Three-day faecal
samples or single-voiding are also alternative to the
24 h collection. With reference to the preparation of
the source for measurement, electrodeposition is the
procedure selected by most of the laboratories,
although there is some lack of information related
to the radiochemical actinides separation method
applied (extraction chromatography or ion exchange
chromatography in some cases). MDA values close
to 0.1 mBq d1 are recommended for the determina-
tion of actinides in urine.
Pure beta emitters in vitro determinations
A total of 26 radiobioassay laboratories participated
in the Eurados action supplying information about
in vitro determinations of beta emitters in biological
samples. LSC (19 facilities) and proportional coun-
ters (6 laboratories) are the techniques selected by
internal dosimetric services. The more typical radio-
nuclides considered in this type of determinations
are 3H and 90Sr; other radioisotopes also evaluated
are 14C, 32P, 35S, 89Sr, 90Y, 125I and 45Ca.
Figure 6. Type of indirect techniques applied for the individual monitoring of European workers.
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Table 15 gives information on the few services that
perform indirect measurements of strontium in
faeces; Table 16 presents the sample procedure and
radionuclides analysed for the determination of beta
activity in urine. Table 17 includes all the informa-
tion collected of source preparation, measurement
procedure and MDA values associated with the eva-
luation of beta-emitters in excreta.
The information collected from European services
that carry out indirect measurements of pure beta-
emitters in excreta shows harmonisation in the
technique selected for in vitro determinations, with
LSC being widely used. Proportional counters are
also available in some services for beta analysis.
With reference to the volume of the collected sample,
laboratories agree in the case of measurement of
90Sr in urine (24 h samples), but there is no such
harmonisation for the determination of 3H in urine,
with volumes varying from 10 ml to 1 litre. The
procedures related to the preparation of the source
for measurement (radiochemical separation and
so on) vary considerably among laboratories. The
Table 13. In vitro detection of actinides in European laboratories: techniques and type of sample.
Ref. Measurement
techniques
Urine samples Urine sample volume Faecal
sample
Faecal
aliquots
At-AR Alpha spectrometry 24 h Full sample,
except for 100 ml
Full
voiding
2 g dry ash
Be-SC Alpha spectrometry 36 or 24 h All 1–4 d One-tenth of the
sample
Cz-RP Alpha spectrometry,
fluorimetry, gamma
spectrometry
24 h not
normalised
on creatinine
From 0.3 litre up to
whole volume
24 h Routinely the
whole sample (1/1)
Ch-PS Alpha spectrometry 24 h 0.25 litre 24 h Whole sample ash
split into two
aliquots
Ch-RA Alpha spectrometry 24 h Whole sample
(0.5–1.0 litre)
Faecal ash Whole collected
sample
De-FJ Alpha spectrometry,
fluorimetry, ICP-MS
24 h, volume mean
value ¼ 1.62 litre
All 24 h 1/3
De-FR Alpha spectrometry,
ICP-MS
24 h, 1.0–2.01;
HNO3
conservation
Alpha spectrometry:
complete sample;
ICP-MS: 5 ml
24 h Whole sample
De-SH Alpha spectrometry,
ICP-MS
24 h 24 h
Es-CI Alpha spectrometry,
KPA(U)
24 h Whole sample/
corrected for
by creatinine,
measurement
3 d
Es-EN Phosphorescence laser
induced
Time, volume 3 ml
Gb-AW Alpha spectrometry Provided at work,
normally requires
5–10 d to produce
required volume
1 litre, normalised to 24 h
using creatinine content
Single
voiding
1/5 or 1/10
dependent upon
sample size
Gb-RW 1.5 litres (U); 6 litres
(Th); 1.5 litres (Pu)
24 h
Gr-GA Alpha spectrometry 24 h 24 h. Urine collection
(1 litre)
Hr-NM Gamma spectrometry 24 h urineþ
creatinine
0.75
It-EN Alpha spectrometry 2 litres during
the weekend
1000 ml for urine One-half of
the sample
Lt-RP Alpha spectrometry 24 h The whole volume of sample
Ro-RB Liquid scintillation
technique
24 h 0.150
Se-HU LABSOC and water
Scintillator
24 h 2 litres
Sk-BO Dual alpha
spectrometry
24 h The whole volume
of 24 h sample
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study of sensitivity of beta analysis (Table 17) shows
a wide range of MDA values depending on the
radionuclide and the counting time used for
the measurement. The determination of tritium in
urine with LSC provides MDAs in the interval of
25–250 Bq l1; lowest MDA reported is 1.2 Bq l1
for a counting time of 100,000 s.
Gamma spectrometry
Information about indirect measurements of gamma
emitters in biological samples was collected from 17
bioassay facilities. Tables 18 and 19 report all the
data supplied by services, showing harmonisation in
the technique selected for bioassay determinations,
HPGe detectors being used most frequently in some
14 facilities. Ge(Li) and NaI(Tl) detectors are also
employed for gamma measurement techniques.
There is agreement between facilities on the volume
of urine and faeces being collected, 24-h samples
with MDA 1 Bq for 137Cs, 60Co and 131I. Differ-
ences are found in the preparation of the source (in
some cases no preparation at all), and in the count-
ing time selected by facilities with resulting MDAs
varying from 0.01 to 1 Bq for typical gamma
emitters.
PAS/SAS monitoring
A difficulty that arises in the measurement of air
samples is the interpretation of the results of concen-
tration of radionuclides in the air, at the location of
the sampler, and not necessarily in the breathing
zone of the worker. A Personal Air Sampler (PAS)
is used to collect a sample representative of the
activity concentration in the air inhaled by the
worker; this allows an estimate of intake of some
typical radionuclides. It is important to know or to
make realistic assumptions about the particle size
distributions in the inhaled material. ICRP78(8)
recommends for a routine monitoring programme
with PAS, the detection of annual intakes that in
total give rise to committed effective doses greater
than one-tenth of the annual dose limit.
Static Air Sampler (SAS) are commonly used to
monitor workplace conditions, but can underesti-
mate concentrations in air in the breathing zone of
the worker (ICRP 78). SAS devices can also provide
useful information on radionuclide composition,
and on particle size if used with a size analyser such
as a cascade impactor.
A total of 13 European laboratories provided data
related to this type of monitoring. UK services
agreed to share with Eurados the information sup-
plied to OMINEX Project(9). Some alpha, beta or
gamma-emitters can be evaluated by PAS/SAS
measurements, particularly 131I and also uranium,
thorium and plutonium isotopes. The results are
not always used for individual dose evaluation.
SAS devices are used in eight facilities of the
Eurados Group, with five services supplying informa-
tion about the application of PAS. Tables 20 and 21
show the more relevant features associated to this
indirect technique. Different MDA values are
obtained in each laboratory depending on the radio-
nuclide and type of monitoring selected.
Assessment of internal doses
The assessment of internal doses following the activ-
ity measurements requires a set of dosimetric steps.
These include the use of biokinetic models, retention
and excretion functions and dose factors. The para-
meters and tools are established and updated in
ICRP publications. In recent years, new recommen-
dations have appeared relating to the evaluation of
internal exposures through the use of the ICRP 66
lung model(10), the new annual dose limits (ICRP
60)(11) and the dose factors defined in ICRP 68(12).
All of these have been summarised in ICPR 78 which
is for individual monitoring.
ICRP developed a more realistic human respira-
tory tract model (Publication 66) and has established
new dose coefficients, which have been adopted in
the revised EURATOM directive. In the assessment
of internal doses from the activities of radionuclides
obtained after individual monitoring, a set of
parameter values must be defined in order to
evaluate the intake and the committed effective
dose, in each internal exposure; more relevant are
the time of intake, the route of intake, AMAD (par-
ticle size), radionuclide and chemical form and type
of absorption.
Table 15. In vitro detection of beta emitters in European laboratories: faecal samples.
Ref. Techniques Radionuclides Faecal sample Faecal aliquot
At-AR LSC, proportional
counting
Full voiding 2 g dry ash
Cz-TE LSC, proportional
counter
90Sr 24 h samples,
minimum of 3 d
Whole sample
De-FJ LSC 90Sr, 89Sr 24 h samples 1/3
Es-CI LSC 90Sr 3 d samples
INDIVIDUAL MONITORING FOR INTERNAL EXPOSURE IN EUROPE
91
Table 16. In vitro detection of beta emitters in European laboratories: urine samples.
Ref. Measurement
techniques
Radionuclides
in urine
Urine samples Urine volume
At-AR LSC, proportional
counting
3H, 14C, 32P,
35S, 125I, 90Sr
3H,14C,32P,35S,125I:
spot urine
3H, 14C, 32P, 35S, 125I: 2 ml
90Sr: 24 h, 100 ml
90Sr: 24 h sample
Be-SC LSC 3H (internal
standarisation)
3H 24 h samples 3  1 ml
Ch-MB LSC 3H Weekly urine samples 0.001 litre
Ch-PS LSC (1)3H, 14C, 32P,
33P, 35S, 45Ca
24 h samples (1) 2 ml
(2) 90Sr, 89Sr (2) 0.5 litre
Ch-RA Proportional counting 90Sr 24 h samples. 0.5–1.0 1 litre 0.5 litre
Ch-RA Direct LSC/Tricarb 3H, 14C, 32P,
33P, 35S, 45Ca
20 ml 0.004 litre
Ch-RC LSC 3H One sample per month 0.001 litre
Ch-SU LSC 3H, 14C, 32P,
33P, 35S, 45Ca
Routine measurements:
20 ml urine samples
monthly/quarterly
2  1 ml
Cz-RP LSC, low-level
proportionalcounter
3H, 90Sr 3H: volume 3H: 0.004/0.01 litre
90Sr: 24 h samples 90Sr: 0.2 litre/whole
portion
Cz-TE LSC, proportional
counter
3H, 90Sr 3H: minimum 10 ml 3H: 0.003 litre
90Sr: 24 h sample 90Sr: whole sample
De-FJ LSC 3H: spot sample 90Sr, 89Sr ¼ 1/3
Others: 24 h
Mean volume: 1.62 litres
14C, 32P, 33P, 35S,
99Tc: 1–5 ml
De-FR LSC 3H, 90Sr 24 h sample; 1.0–2.01 litres;
HNO3–conservation
3H: 5 ml; 90Sr 500 ml
Dk-RI LSC 3H One sample every
month 100 ml
Es-CI LSC 3H, 14C, 32P,
35S, 90Sr
Time Variable
Es-TR LSC 3H All urine on 12 h in the night 1 ml
Gb-AW 3H in urine 3H Weekly samples of 150 ml 0.5 ml
Gb-RW 3H, 90Sr/90Y Volume ¼ 1.5 litre
Hr-NM Beta counting 90Sr 24 h samplesþ creatinine 0.25 litre
Hu-RR LSC 3H, 14C Volume: minimum 1 litre 0.02 litre
Ie-SV 32P, 89Sr 24 h samples 20 cm3
Lt-RP Gross beta
counter, LSC by
Tri-Carb 2770
TR/SL
Gross beta,
3H, 90Sr/90Y
24 h samples The whole volume
of sample
Nl-RE LSC 3H 0.1 litre; no normalisation 0.002 litre
No-IE LSC 3H Weekly samples during shut
down periods, beyond that
monthly samples
0.7 ml
Ro-CN LSC 3H, 14C Monthly sample (50 ml) 1 ml
Ro-PR Beta activity
measurements
with G-M in
anticoincidence
or plastic detectors
90Sr 24 h samples or creatinine
method (minimum three
excretions)
Whole quantity
Se-RI LSC 3H Single sample 1–20 ml depending on the
activity of the sample
Sk-BO LSC, multi-low-level
counting
3H, 90Sr 3H: single sample, 50 ml 3H: 1 or 20 ml (distillation)
90Sr: 24-h sample 90Sr: 25 ml
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It is important that the doses received by work-
ers travelling and working in different facilities be
assessed in a similar way by each internal dosi-
metric services. Information about reference levels
(annual dose limit, lowest reporting dose and
investigation level) was collected from the answers
of Eurados questionnaire Q2 in each country and
are listed in Table 22. The existence or not of a
national record of doses is also reported. An
important point to focus on is the software and
dosimetric tools used in each service to evaluate
internal doses and the assumption of AMAD con-
sidered together with the lung model (ICRP 30/
ICRP 66), the dose factors (ICRP 26/ICRP 68)
and the type of individual monitoring programmes
(ICRP 54/ICRP 78).
The information provided by the 26 participating
countries indicates that 60% have implemented an
annual dose limit of 20 mSv for internal exposures.
The remaining 40% applied a limit of 100 mSv in 5 y
or 20 mSv y1 during 5 y with a maximum dose of
50 mSv y1 in this period. Out of the 24 countries, 14
included in Table 22, have or will have a National
Record of Doses.
Software available to European services for dose
assessments include IMBA, LUDEP, IMIE,
Mondal/Moldes, MIRD, INDAC, Cindy, Remedy
and Retex. It is important to note that not all of
them include the latest ICRP recommendations
implemented in the EU directive. It is clear that
computer software supports the best estimate of
intakes and the resultant committed effective dose,
but they must be appropriate to the application. One
of the more important conclusions of the Eurados
study is the need for harmonisation in the evaluation
process of internal exposures after the direct/indirect
measurement of the retained/excreted activity of the
radionuclide of interest.
Table 18. In vitro detection of gamma emitters in European laboratories: type of samples.
Ref. Samples Urine samples Urine volume Faecal samples Faecal aliquot
At-AR U, F 24 h sample Whole volume
of sample
Full voiding 2 g dry ash
Cz-DU U, F 24 h sample 0.5 litre 24 h sample Aliquot for 1 d
Cz-RP U, F 24 h sample Whole volume
of sample
24 h sample 1
Cz-TE U, F 24 h sample, minimum 3 d 0.5 litre 24 h sample,
minimum 3 d
0.25 litre
Dk-RI U Not routine 100 ml
Gb-AW U, F
Hr-NM U, F 24 h urine sampleþ creatinine 0.75 litre
It-AG U 24 h sample 130 ml
It-BU U Collection of 100 ml of urine
at the end of the working day.
In case of positive result,
collection of 24 h urine.
The frequency of sampling
is daily for 99Tcm, weekly
for other isotopes
100 ml, 1 litre
It-EN U Collection of whole urine
excretion in 4 d working
shifts
1000 ml
It-ON U One excretion once a
week (Thursday) at about
10:00 am, no creatinine,
standard daily volume
considered
0.1 litre
Lt-RP U 24 h sample Whole volume
of sample
Ro-CN U 24 h sample 1 litre
Ro-PG U 24 h sample 0.1 litre
Se-OK Lung tissue (in vitro)
Se-RI U 24 h sample 24 h sample, 5 d
Si-OS Foodstuff, fodder
Sk-BO U, F 24 h sample 0.5 litre 24 h sample Whole volume
of 24 h sample
U, urine and F, faeces.
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Application of ICPR publications varies greatly
among facilities, for instance, in relation to the lung
model (ICRP 30/ICRP 66), the dose factors (ICRP
26/ICRP 68) and the type of individual monitoring
programmes (ICRP 54/ICRP 78). In some cases
a combination (mixing new and old recommen-
dations) is used in the software for internal dose
calculations. Other parameters affecting dose calcu-
lations, such as the AMAD of particles, were also
studied in the Eurados action. The results show that
an AMAD of 5 mm is selected in 50% of the countries
participating in the study, with values ranging from
1 to 10 mm.
Using the guidance of the IAEA safety guide No.
RS-G-1.2(13), the application of reference levels asso-
ciated with monitoring workers with risk of internal
exposures was analysed in different European
countries. Investigation levels and recording levels,
expressed as an appropriate fraction of the committed
effective doseE50 limit, are of relevance to monitoring
for internal contamination in the case of occupational
intakes of radionuclides. Eurados harmonisation
action collected information about the lowest
reported dose and the investigation level established
in each country. The results are presented in Table 22.
In some instances different answers were reported by
facilities of the same country.
The lowest reporting level applied in internal dosi-
metric services in Europe are presented in Figure 7.
This value is the level above which the calculated
dose is entered in the individual exposure record of
the worker. Approximately 50% of the services use
recording levels in the interval 0.1–0.3 mSv. A total
of five laboratories report any estimation of dose
(from measured Activity >AMD), five countries
use 1 mSv as a recording level and the remaining
five prefer a lower reference level of 0.01 mSv.
Figure 8 shows the investigation level employed by
different European countries, when dealing with
individual monitoring of workers for internal occu-
pational exposures. Three distinct groups emerge
from the data: eight countries apply investigation
levels in the interval 0.1–0.3 mSv, seven count-
ries reported values of 1–2 mSv and five selected
5–6 mSv as investigation level.
The extensive information obtained from this sec-
tion of the Eurados study (Table 22) yields an over-
view of the status of evaluation processes for internal
doses in European services. A further harmonisation
action in this matter is recommended which would
investigate in detail dosimetric tools, training activ-
ities and availability of qualified experts in each
laboratory for the optimisation of procedures invol-
ving intake and dose estimations.
Table 20. PAS/SAS monitoring in European facilities.
Ref. Technique Radionuclides Type of sample
Cz-DU SAS, monitoring with
natural radioactivity
compensation
Alpha and beta emitters Aerosol filters 50 and 100 mm
Cz-RP Gamma spectrometry
of the filters
Gamma emitters Aerosol filter, charcoal cartridge
De-SH SAS 241Am and alpha-emitting
nuclides of U and Pu
Alpha-activity deposited on filters
Ee-AS Sampling on filter and
measurement of total
alpha activity
Sum long-lived alpha emitters Filter
Es-EN SAS 238U, 235U AMAD ¼ 5 mm
Es-TR Air sampling
(static and moving)
131I, 58Co, 60Co, 54Mn,
124Sb, 51Cr, 59Fe
Charcoal and paper filters
Gb-AW PAS Alpha emitters Glass fibre filter
SAS Alpha and beta emitters Glass fibre filter and cellulose filters
Gb-RR SAS, PAS Uranium (238U, 235U and 234U) Roteroe Mitchell Bird and Tole (SAS)
Gb-RW PAS (gross alpha) Uranium
PAS (thorium)
(gross alpha)
Thorium (232Th, 228Th)
PAS (plutonium)
(gross alpha)
238Pu, 239þ240Pu
It-BU Air pump in working
rooms, time of
sampling: 1 h
131I Active charcoal cartridge for gas,
paper filter on cartridge for
particulate
Lt-RP SAS 131I Aerosols
Se-HU EDGAR
Si-KR SAS Gamma emitters Glass fibre filter, charcoal filter
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Legal aspects and quality assurance
Information relating to the status of implementation
of Council Directive 96/29, regulatory bodies and the
legal requirements to be met by internal dosimetric
services were collected for each European country.
As an objective is harmonisation of requirements
and procedures in this area, focus should be placed
on the following points:
(1) Status of implementation of Council Directive
96/29 in European countries.
(2) Current status within European states of
requirements for approved internal dosimetric
services:
(a) National regulatory body: procedures to be
undertaken to achieve the status of an
approved internal dosimetric service.
(b) National legislation, technical guidelines, offi-
cial protocols and so on.
(c) Procedures to demonstrate compliance with
regulatory requirements.
(3) International recommendations and guidelines to
take into account: ICRP publications, ISO and
ANSI standards, IAEA safety series and so on.
(4) Quality assurance and quality control procedures:
the participation of internal dosimetric services in
exercisesofintercomparisonofmeasurements and
dose assessments are highly recommended.
The previous report on ‘Implementation of stand-
ards’ (E. Fantuzzi et al.) in this publication, shows a
reference of documents, standards and recommenda-
tions established at an international level, to be
applied in internal dosimetry facilities; the objective is
to provide each service of appropriate equipments
and procedures, with a quality assurance programme
that guarantees the reliability in the results of
measurements.
The extensive information related to legal aspects
of internal dosimetric services in Europe was sum-
marised and is presented in Table 23, providing an
overview of how European countries are responding
Table 21. Indirect techniques and MDA associated with PAS/SAS Monitoring in European facilities.
Ref. Technique Air flow Respirable fraction MDA
Cz-DU SAS, monitoring with natural
radioactivity compensation
Gas-flow meter Total Alpha: 30–300 Bq;
beta: 100–1000 Bq
on filter
Cz-RP Gamma spectrometry of the
filters
30–120 m3 h1 (SAS
including six stages
cascade impactor)
Total (respirable
fraction by using
cascade impactor)
De-SH SAS sampling on filter and 10–12 m3 h1 Total 2.50 mBq m3
measurement total alpha
activity
Ee-AS SAS High-volume–air-
sampler, vacuum
system, other
Total 5.00 mBq m3
Es-EN Air sampling (static and moving) 1.2 m3 h1 Total 0.10 Bq
Es-TR Air pump in working rooms,
time of sampling: 1 h
50 l min1 0.01% 0.10 Bq m3
Gb-AW PAS 2 l min1 Total fraction 5.00 mBq
SAS 50 l min1 Total fraction 1.80 mBq
Gb-RR PAS (uranium) (gross alpha) Flow rate ¼ 2 l min1 Total fraction; breathing
rate ¼ 1.2 m3 h1
0.02 Bq total
uranium
PAS (thorium) (gross alpha) Flow rate ¼ 2 l min1 Total fraction; breathing
rate ¼ 1.2 m3 h1
0.02 Bq 232Th;
0.02 Bq 228Th
PAS (plutonium) (gross alpha) Flow rate ¼ 2 l min1 Total fraction; breathing
rate ¼ 1.2 m3 h1
0.02 Bq (Pu-alpha)
It-BU SAS 25 l min1 Fraction 1.05 Bq m3
Lt-RP EDGAR 50 l min1 Total 0.10 Bq per filter
Se-HU SAS
Si-KR PAS
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to this issue. As first conclusion, the almost general
implementation of the Council Directive 96/29 in the
group of 26 countries collaborating with Eurados for
harmonisation.
INVENTORY FOR EACH MEMBER STATE
A network of experts involved in dosimetry from
26 countries collaborated with Eurados. The infor-
mation collected gives a good overview of the sta-
tus of internal dosimetry in Europe in 2001. The
contact persons, in each country, took responsibil-
ity for distributing the questionnaire Q2 among
laboratories undertaking internal dosimetry. The
answers yielded an overview of services, methods,
type of exposures and national regulation. The co-
ordinators in each country supplied other relevant
information such as the number of approved
services, total number of facilities and a list of
other services (in case not all collaborated with
Eurados). A summary of the facilities in each
European country performing internal dosimetry
is presented as follows.
Austria (AT)
Austria is a European member state with five
approved internal dosimetric services. ARC
Seibersdorf Research Centre and Graz University
Medical Centre collaborated with Eurados
(Table 24). They outlined the methods used to eval-
uate the different types of internal exposures:
research, decommissioning, medical field, non-
nuclear industry and waste conditioning manage-
ment. Both services use direct techniques to measure
gamma-emitters in the whole-body and radioiodine
in the thyroid. ARC also performs in vivo measure-
ments for actinides in the lungs and can perform
Figure 8. Investigation level associated with the monitoring of internal exposures in Europe.
Figure 7. Lowest reported dose associated with the monitoring of internal exposures in Europe.
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Table 23. Implementation of Council Directive 96/29, and legal aspects by country.
Country Implementation
96/29 Directive
Regulatory body Legal requirements
AT Yes, 2002 Ministry of Agriculture,
Forestry, Environmental
and water
100% European Directive
BG Yes, 2000 BNSA Ministry of Health
Nuclear Regulatory
Agency (NRA)
CH Yes Federal Office of Public
Health (BAG)
Radiological protection law (1991) and
ordinance (1994), personal dosimetry
Federal Nuclear Safety
Inspectorate (HSK)
ordinance (1999)
CS Yes, BSS is
implemented
Federal Ministry of
Health
Occupationally exposed to open
sources shall be subjected to internal
dose monitoring programme
CZ Yes State Office for Nuclear Safety Licence issued by the Regulatory
SU´JE Praha Body according to the relevant legal act
DE Yes, 2001 Federal and state authorities Radiation Protection Ordinance
Strahlenschutzverordnung
StrlSchV
Guideline on health physics for the
determination of body doses
General calculation basis for the
determination of body doses caused by
internal radiation exposure
Accreditation by state government
DK Yes NIRH (SIS)
EE Radiation Act Radiation Protection Centre Radiation Act (1997) as amended
(1997) and
regulations of
Government
and Ministers
Government Regulation 37 ‘Statute
of the National Dose Register of
Radiation Workeers; Procedure
for Certifying Radiation Workers
and Issuing Certificates’
Regulation of the Minister of the
Environment No. 49 ‘Inhalation
and Ingestion Dose Coefficients
for Radiation Workers’ (1999)
ES Yes, 2001 CSN (Nuclear Safety Council) Guidelines established in the CSN
Guide 7.1 (GSG- 07.01, 1985)
published by the Spanish
Regulatory Body: ‘Guı´a
de Seguridad 7.1. del Consejo
de Seguridad Nuclear: Requisitos
te´cnico administrativos para
los Servicios de Dosimetrı´a
Personal Individual’.
Ref: ISBN 84-87275-46-X
GB Yes, 2000 Health and Safety Executive Ionising Radiations Regulations, 1999
GR Yes Greek Atomic Energy
Commision
HU Yes Ministry of Health In case incorporation could occur,
procedures are published in
methodological letters by NRIRR in
co-operation with the competent
professional board
Appropriate dosimetric surveillance
shall be provided by the licensee,
in accordance with the approved
Workplace RPR. The laboratory
performing the monitoring of
internal exposure shall be accredited
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Table 23. Continued.
Country Implementation
96/29 Directive
Regulatory Body Legal requirements
For the purposes of the central
registry the results beta, neutron, and
internal dosimetric investigations shall
be communicated to the NRIRR with a
frequency prescribed for the given
workplace
IE SI 125 of 2000 Radiological Protection
Institute of Ireland
Demonstrate compliance with dose limits
IT Yes, but in dosimetric
services not yet
Decreto Legislativo n. 230/95,
modified by D.L. n. 241/00
and by D.L. n. 187/00. All of
them are implementation
of EU Directive
The requirements are still not well
specified by the current laws
Legal requirements in progress
ANPA
LT Yes, BSS is
implemented
Ministry of Health,
Radiation Protection
Centre
100% European Directive
NL Yes, 2002 Ministry of Social
Affairs and Employment
No specific requirements
NO No NRPA FOR 2003-11-21 no. 1362: ‘Forskrift om
stralevern og bruk straling’
PT Under Implementation Not available
RO Yes, 2000 CNCAN ICRP 60 and IAEA- BSS-115 application
Fundamental norms for radiological
security published in Romanian Official
Monitor no. 404 bis/2000
SE Yes, 1998 Swedish Radiation
Protection Authority (SSI)
Fullfil stipulated (SSI FS 1998:
5/2000:10) control program defined by
three categories, group of reference—
group with work giving higher risk for
intake—incidents with known intake
Dose assessment, effective dose (E50)
using dose coefficients from
96/29/EURATOM Appendix III,
according to intake type
(inhalation/ingestion)
Report to National Dose Register
if E50 1 mSv. If E50 5 mSv full
incident report immediately to SSI
WBC shall be performed according
to a documented procedure that is
approved by the SSI (SSI 2000:10)
SI Yes Ministry of Health, Slovenian
Radiation Protection
Administration (SRPA)
Radiation Protection and Nuclear
Safety Act (O.J. RS No. 50/2003,
46/2004) and underlying legislation.
Prior the issuing a license the
assessment of internal exposure as
well as a monitoring programme
are prepared. The assessment and
the programme are subjects of a
consultation with an approved
expert and should finally be approved
by the SRPA. The internal exposure
monitoring programme become a part
of a licensing conditions
Different data from different services
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bioassay evaluations using spectrometry on urine
and faeces samples. Alpha spectrometry is used for
actinides, while LSC is used for beta emitters.
Three other internal dosimetric laboratories oper-
ate in Austria. They are small services, situated in
hospitals, and only monitor personnel in their
nuclear medicine departments (Table 25).
Belgium (BE)
SCK–CEN Mol is an important research centre in
Belgium with a great reputation in the field of Inter-
nal Dosimetry (Table 26). This institute evaluates
internal doses using in vivo and in vitro measure-
ments. In Belgium the risk of internal exposure
comes from the nuclear fuel cycle workplace and
research activities. Gamma emitters are detected
using whole-body counting. The assessment of acti-
nides is carried out using results from lung counting
and alpha spectrometry (bioassay). LSC is used to
assess beta exposures. As there is no national require-
ment for approval, the SCK–CEN Mol laboratory is
not a legally approved internal dosimetric service. Of
particular interest here is the methodology that has
been developed for the evaluation of accidental con-
tamination of a wound by radionuclides.
Bulgaria (BG)
Bulgaria is an eastern European country collabor-
ating with Eurados (Tables 27 and 28). There are
three legally approved internal dosimetric services in
Bulgaria. The department of individual dosimetry at
the Kozlodui Nuclear Power Plant in Bulgaria is well
equipped with three WBCs. This plant answered
questionnaire Q2 (internal dosimetry) and indicated
that exposed workers at risk of internal exposures
are monitored using whole-body counting and lung
counting for actinides. Indirect techniques are not
used for the assessment of internal doses.
The national regulatory body in Bulgaria is the
Nuclear Regulatory Agency (NRA). As metrology is
regulated and well organised, metrology certification
plays the role of accreditation.
Table 24. Internal dosimetric services in Austria (AT) collaborating with Eurados.
Facility Exposure Direct techniques Indirect techniques
ARC Seibersdorf
Research GmbH
Research, decommissioning,
medical field, non-nuclear
industry, waste conditioning
management
WBC, lung counting,
thyroid counting
Spectrometry for
urine and faeces
(alpha spectrometry
and LSC)
Pru¨fstelle fu¨r
Strahlenschutz,
Landeskrankenhaus-
Universita¨tsklinikum
Graz
Research, medical field,
non-nuclear industry
WBC, thyroid counting —
Table 25. Other internal dosimetric services in Austria (AT).
Country Facility
Austria SMZ Ost
Allgemeines Krankenhaus
der Stadt Wien
Universita¨tsklinikum
Innsbruck
Table 26. Internal dosimetric services in Belgium (BE).
Facility Exposure Direct
techniques
Indirect
techniques
SCK–CEN
Mol
NFC,
Research
WBC, lung
counting,
wound counting
Alpha
spectrometry,
LSC
Table 27. Internal dosimetric services in Bulgaria (BG)
collaborating with Eurados.
Facility Exposure Direct
techniques
Indirect
techniques
Kozloduy
NPP
NPP WBC, lung
counting
—
Table 28. Other internal dosimetric services in Bulgaria
(BG).
Country Facility
Bulgaria National Centre of Radiobiology
and Radiation Protection
Laboratory (Ministry of Health)
Military Medical Academy
(Military Hospital) in Sofia
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Switzerland (CH)
Seven internal dosimetric services are legally
approved in Switzerland. All of them supplied data
on techniques and procedures, explaining that
laboratories deal with internal exposures in research
workplaces, medical field and non-nuclear industry.
Direct (whole-body and thyroid counting) and indir-
ect techniques are available for the measurements of
radionuclides and the assessment of effective doses
(Table 29).
Serbia and Montenegro (CS)
Two Internal dosimetric services are legally
approved in the former Yugoslavia (Table 30).
They are involved in the evaluation of doses in the
medical and research fields and non-nuclear indus-
tries. Direct and indirect techniques are available to
determine internal exposures. Special attention is
given to the doses associated with military applica-
tions using depleted uranium.
Czech Republic (CZ)
There are four Internal dosimetric services in the
Czech Republic. All facilities are legally approved
and collaborated with Eurados (Table 31). Direct
and indirect techniques are available for the assess-
ment of effective doses coming from all types of
internal exposures from NPPs, nuclear fuel cycle,
Table 29. Internal dosimetric services in Switzerland (CH).
Facility Exposure Direct techniques Indirect techniques
PSI–Paul Scherrer Institute Research WBC, thyroid
counting
LSC, spectrometry for
urine and faeces
Institut Universitaire de
Radiophysique Applique´e
Research, medical field,
non-nuclear industry
Thyroid counting LSC, alpha spectrometry,
proportional counting
BKW FMB Energie AG NPP WBC —
RC Tritec Ltd Research — LSC of urine samples
Suva (Swiss National
Accident Insurance Fund)
Non-nuclear industry — Urine measurements
mb-microtec ag Industry (tritium) — LSC
Whole body counter
University Hospital Basel
Medical field WBC —
Table 30. Internal dosimetric services in Serbia and Montenegro (CS).
Facility Exposure Direct techniques Indirect techniques
Institute of Occupational
Health, Belgrade
Medical field — Spectrometry for urine
Institute of Nuclear
Sciences Vinca
Research, medical field,
non-nuclear industry,
military application of DU
WBC, lung counting,
thyroid counting
Alpha and gamma spectrometry,
3H measurements
Table 31. Internal dosimetric services in Czech Republic (CZ).
Facility Exposure Direct techniques Indirect techniques
National Radiation
Protection Institute
NPP, research, medical field,
decommissioning, non-nuclear
industry, others
WBC, skull counting Alpha and gamma spectrometry,
LSC, low-level beta, fluorimetry
Personal Dosimetry
Service–Temelin
NPP WBC, thyroid counting Gamma spectrometry
(urine, faeces), LSC (urine),
proportional counter (90Sr)
Nuclear Research
Institute Rez
Research, medical field WBC, thyroid counting —
Dukovany Nuclear
Power Plant
NPP, NFC WBC, thyroid counting Gamma spectrometry
(urine, faeces)
INDIVIDUAL MONITORING FOR INTERNAL EXPOSURE IN EUROPE
105
research, medical field, decommissioning and
non-nuclear industries. Special attention was given
to the evaluation of actinides in the skull with
a methodology being developed at the National
Radiation Protection Institute in Prague.
Germany (DE)
Twenty-five services are involved in the assessment
of internal exposures employing both direct and
indirect techniques. Eight laboratories answered
questionnaire 2, and the information related to mon-
itoring programmes and techniques is shown in
Table 32.
Laboratories receive their authorisation to carry
out measurements from local government. Other
internal dosimetric services in Germany (not partici-
pating) are presented in Table 33.
Denmark (DK)
This Scandinavian country has no legally approved
internal dosimetric services, but the Riso
national laboratory performs in vivo and in vitro
measurements of exposed workers involved in
research activities, decommissioning and non-
nuclear industries (Table 34).
Estonia (EE)
There is no legal requirement to be an approved
service. One laboratory evaluates internal doses
using SASs in workplaces that are processing raw
materials containing natural uranium and natural
thorium (Table 35). Measurements of total activity
of long-lived alpha emitters in the air are made at AS
Ecosil. This facility provides a measurement service
for the factory of Silmet. The internal doses of the
factory workers are estimated on the basis of the
SAS results.
Spain (ES)
There are nine internal dosimetric services legally
approved by the Nuclear Safety Council (national
regulatory body) to perform the official evaluation of
internal doses in Spain (Table 36). Eight services are
dealing with exposures in NPPs (operatives or in
phase of decommissioning) carrying out in vivo
measurements of gamma-emitters deposited in
the body.
CIEMAT is a research centre with two of its
laboratories being responsible for using direct and
indirect techniques to assess internal doses. The
CIEMAT internal dosimetric service is the only
place in Spain which performs measurements of acti-
nides in lungs and in bone and where bioassay deter-
minations can be carried out. Workers involved in the
fabrication of nuclear fuel elements for NPPs are
routinely monitored at CIEMAT with LEGe detec-
tors for the measurement of 3.6% enriched uranium in
lungs. The fabrication facility is authorised to per-
form indirect determinations of uranium in urine
(Phosphorescence laser induced technique) and
uranium in SASs.
Table 32. Internal dosimetric services in Germany (DE) collaborating with Eurados.
Facility Exposure Direct techniques Indirect techniques
Universita¨tsklinikum Essen-
Klinik fuer Nuklearmedizin
Medical field WBC, thyroid detector Spectrometry
ICP-MS
A.K. St Georg Abteilung fu¨r
Nuklearmedizin, Hambourg
Medical field 131I in thyroid Spectrometry for
urine and faeces
Landesanstalt fu¨r Umweltschutz
Baden-Wu¨rttemberg, Karlsruhe
WBC —
Bundesamt fu¨r Strahlenschutz (BfS) Fission and activation
products, 125I
WBC, thyroid detector —
Framatome ANP GmbH,
Erlangen
Decommissioning — —
Siemens AG, Power Generation,
DP Hanau
NPP, decommissioning WBC, lung counting
(þother organs,
wound counting)
—
Forschungszentrum, Ju¨lich,
Inkorporationsmessstelle,
Ju¨lich
NPP, NFC, research,
medical field, decommissioning,
non-nuclear industry
WBC, thyroid detector Alpha spectrometry,
ICP-MS
Forschungszentrum Karlsruhe,
Inkorporationsmessstelle, Karlsruhe
NPP, NFC, research,
medical field, decommissioning,
non-nuclear industry
WBC, lung counting,
thyroid counting
Alpha spectrometry,
ICP-MS
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United Kingdom (GB)
A total of 10 internal dosimetric services operated
in the United Kingdom; 9 of which are legally
approved (Tables 37 and 38). Three collaborated
with Eurados, supplying information about meth-
ods and procedures. Information of UK was sup-
plied by NRPB, as co-ordinator of the OMINEX
project. This project is supported by EC under the
fifth framework programme and studies the opti-
misation of individual monitoring of occupational
exposures.
Greece (GR)
The facility in Greece, dealing with the evaluation of
internal exposures, is made up of two research labora-
tories (the Department of Environmental Radioac-
tivity of the Greek Atomic Energy Commission and
the Ioannina University Medical Physics Labora-
tory). Typical exposures that are assessed are related
to research activities, medical field and non-nuclear
industry (Table 39). Special attention was also given
to Greek soldiers and personnel returning from
Kosovo who were involved in the Balkans war.
The Medical Physics Department at the University
of Athens Medical School will probably, in the future,
be capable of performing in vivo measurements
(WBC) for the assessment of internal exposures.
Croatia (HR)
There is one legally approved internal dosimetric
service in Croatia (Table 40), the Department of
Nuclear Medicine and Radiation Protection. Here
in vivo (WBC, thyroid counting) measurements and
also indirect techniques (spectrometry for urine and
faeces) are carried out to assess internal exposures.
Table 33. Other internal dosimetric services in Germany (DE).
Country Facility
Germany Freie Universita¨t Berlin, Inkorporationsmessstelle, Berlin
Universita¨t Tu¨bingen, Strahlenschutzbereich UKT, Tu¨bingen
Bayerisches Landesamt fu¨r Umweltschutz, Kulmbach
Justus-Liebig-Universita¨t Gießen, Landesmessstelle, Gießen
Universita¨t Hamburg, Abteilung fu¨r Nuklearmedizin, Hamburg
Medizinische Hochschule Hannover, Landesmessstelle, Hannover
Landesanstalt fu¨r Arbeitsschutz, Du¨sseldorf
Klinikum der Universita¨t zu Ko¨ln, Inkorporationsmessstelle, Ko¨ln
Universita¨t Mu¨nster, Klinik und Poliklinik fu¨r Nuklearmedizin,
Mu¨nster
Bayer AG, Metabolismus und Isotopenchemie, Wuppertal
RWTH Aachen, Abteilung Strahlenschutz, Aachen
Klinikum der Johannes-Gutenberg-Universita¨t Mainz,
Inkorporationsmessstelle, Mainz
Johannes-Gutenberg-Universita¨t Mainz, Institut fu¨r
Kernchemie, Mainz
Landesamt fu¨r Umweltschutz und Gewerbeaufsicht, Oppenheim
E.ON Kernkraft GmbH, Messstelle Inkorporation, Brokdorf
Kernkraftwerk Kru¨mmel GmbH, Inkorporationsmessstelle, Geesthacht
VKTA Rossendorf e.V., Inkorporationsmessstelle, Dresden
Table 34. Internal dosimetric services in Denmark (DK).
Facility Exposure Direct techniques Indirect techniques
Applied Health Physics,
Riso National Laboratory
Research, decommissioning,
non-nuclear industry
WBC LSC, total beta, gamma spectrometry
Table 35. Internal dosimetric services in Estonia (EE).
Facility Exposure Direct
techniques
Indirect
techniques
AS
Ecosil
Processing of raw
material containing
Unat and Thnat.
Remediation of the
Simillama¨e Radioactive
Tailings Pond
SAS
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Hungary (HU)
At present there are a total of three accredited IDSs
out of four in Hungary; only one is legally comm-
issioned for country-wide record keeping. The
National Research Institute for Radiobiology and
Radiohygiene performs in vivo (WBC) and in vitro
measurements (LSC and gamma spectrometry)
on exposed workers employed in NPPs, nuclear
fuel cycle, research activities and medical field
(Table 41). The KFKI Atomic Energy Research
Institute provides services on in vivo monitoring by
WBC and thyroid counting for the whole centre
(research reactor, activation analysis, etc.) and,
upon request, for other institutions (isotope produc-
tion, NPPs, research activities, etc.) as well as for the
public. The other two laboratories performing inter-
nal dosimetry in Hungary are listed in Table 42.
Ireland (IE)
There is only one internal dosimetric service in Ire-
land and it is approved by the national authority. It
performs evaluations of internal exposures in
Table 36. Internal dosimetric services in Spain (ES).
Facility Exposure Direct techniques Indirect Techniques
CIEMAT (Centro de Investigaciones
Energe´ticas Medioambientales y
Tecnologicas)
NFC, research,
medical field,
decommissioning,
waste management
WBC, lung counting,
thyroid counting,
Bone counting
Alpha spectrometry, LSC
ENUSA NFC (lung counting
at WBC-CIEMAT)
Uranium in urine
(phosphorescence
laser induced), SAS
TECNATOM-Servicio de
Dosimetrı´a
NPP,
decommissioning
WBC, Quicky, thyroid
counting
—
Central Nuclear Asco NPP WBC —
Central Nuclear Vandellos II NPP Quicky, thyroid counting —
Central Nuclear Trillo NPP WBC —
Central Nuclear Almaraz NPP WBC —
Central Nuclear Jose Cabrera
(Zorita)
NPP WBC —
Central Nuclear Cofrentes NPP WBC —
Central Nuclear Sta Marı´a
de Garo~na
NPP WBC —
Table 37. Internal dosimetric services in the United Kingdom (GB) collaborating with Eurados.
Facility Exposure Direct techniques Indirect techniques
Rolls Royce Marine
Operations Limited
NFC — Routine: uranium in SAS
(also PAS measurements and
determination of uranium in urine)
AWE plc Research,
decommissioning
Lung counting for actinides,
wound monitoring (incidents)
3H in urine; uranium and plutonium
in PAS/SASþurine/faeces
RWE NUKEM Ltd NPP, NFC, research,
decommissioning,
non-nuclear industry
WBC, thyroid counting,
lung counting
3H in urine; gross beta in urine;
PAS (and SAS); U, Th, Pu, in urine;
Pu in faeces; 90Sr/90Y in urine
(incidents), thorium in faeces
(incidents)
Data obtained from OMINEX questionnaire
Table 38. Other internal dosimetric services in the United
Kingdom (GB).
Country Facility
United Kingdom BNFL Sellafield
BNFL Springfields
RWE Nukem (Dounreay)
DSTL Radiological
Protection Services
NRPB (internal dosimetry,
tritium, in-urine only)
Nycomed Amersham
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research activities, the medical field and non-nuclear
industry. Whole-body counting and bioassay meas-
urements in urine samples are carried out in
St Vincent’s University Hospital (Table 43).
Italy (IT)
A total of 18 facilities in Italy are involved in the
assessment of internal exposures. There is no legal
requirement for the approval of internal dosimetric
services. Eight laboratories collaborated with Eura-
dos (Table 44).
The Casaccia radiobioassay laboratory is the only
facility measuring the uranium in urine using alpha
spectrometry. In the near future it will also be in a
position to measure the thorium in urine. Further-
more, in time the Casaccia centre will also be able to
measure U in urine with ICP-MS.
There are 10 other whole-body counting facilities
in Italy but they have not provided information
related to their activities. These facilities are listed
in Table 45.
Lithuania (LT)
There are two internal dosimetric services in Lithuania,
the whole-body counting facility at the Ignalina
Nuclear Power Plant and the in vitro laboratory at
the Radiation Protection Centre. The second facility
examines exposures at different workplaces: NPPs,
research, decommissioning, medical field and non-
nuclear industries. The evaluations of internal doses
were carried out using indirect techniques only, but
since 2004 direct techniques (whole-body and
thyroid counting) are available at the Radiation
Protection Centre (Table 46).
Netherlands (NL)
One internal dosimetric service, at the NRG Insti-
tute, operates in the Netherlands. Here whole-body
counting, a direct technique, is used for in vivo detec-
tion of gamma-emitters in the body. LSC is used for
in vitro monitoring of beta emitters (Table 47).
Norway (NO)
There are three internal dosimetric services operat-
ing in Norway and there is no legal requirement
for approval. Institut for energiteknikk, IFE, has
laboratories which can perform direct (whole-body
and thyroid counting) and indirect techniques (spec-
trometry for urine samples) to monitor exposed
workers in research institutes (Tables 48 and 49).
Poland (PL)
One internal dosimetric service exists in Poland (no
legal approval). It undertakes in vivo measurements,
detecting radioiodine in the thyroid of exposed med-
ical workers (Table 50).
Portugal (PT)
There is no legally approved internal dosimetric
service in Portugal. One whole-body counting facil-
ity is available at the Nuclear Technology Institute
(ITN) in Lisbon. This is involved in monitoring
exposure of workers medical and research fields
(Table 51).
Romania (RO)
There are five legally approved internal dosimetric
services in Romania (Table 52). All services supplied
data relating to their monitoring programmes.
Romanian laboratories are capable of undertaking
direct (WBC, thyroid counting) and indirect
Table 39. Internal dosimetric services in Greece (GR).
Facility Exposure Direct techniques Indirect techniques
Greek Atomic Energy
Commission–Department of
Environment Radioactivity
Research, medical field,
non-nuclear industry, Greek
soldiers and personnel from
Kossovo
WBC, thyroid uptake Alpha spectrometry for urine
Ioannina University Medical
Physics Laboratory
Research, medical field WBC, partial whole-body
counter (hand)
Alpha spectrometry for urine
Table 40. Internal dosimetric services in Croatia (HR).
Facility Exposure Direct
techniques
Indirect
techniques
Department
of Nuclear
Medicine and
Radiation
Protection
Medical
field
WBC,
thyroid
counting
Spectrometry
for urine and
faeces
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(spectrometry for alpha, beta and gamma-emitters in
urine) methods. Internal exposures come from a
variety of sources: one NPP, research activities, the
medical field and members of the public who have
been affected by Chernobyl accident.
Sweden (Se)
There are 12 institutes performing internal dosi-
metry in Sweden. To date there is no legal
approval system in place. Three services provided
data about methods and procedures for this
study (Table 53).
With reference to dose assessment in Sweden, as in
Norway and Denmark, the radiation protection
authorities are capable of evaluating internal doses,
but the responsibility for that is, under normal con-
ditions, given to workplaces.
Westinghouse Atom AB has a lung counter with
low-level planar detectors especially designed for
measurements in lungs. The in vivo assessment of
thorium is carried out at the Lund University, in
collaboration with SSI, which uses recently calib-
rated instrument developed for collecting thoron-
progeny in exhaled air. Other internal dosimetry
services in Sweden are listed in Table 54.
Slovenia (Si)
There are three internal dosimetric services in
Slovenia (Table 55), one of them is legally approved.
In addition to the above-mentioned services one
service, which is approved, does not perform internal
dosimetry. Monitored workers work mainly in two
facilities: the Krsˇko Nuclear Power Plant and the
Nuclear Medicine Department at the University
Medical Centre. Internal occupational doses in the
Krsˇko Nuclear Power Plant are evaluated applying
direct techniques (WBC, lung or thyroid counting).
Intakes due to work in research or medical facilities
are calculated using measurements at the WB coun-
ter at the Nuclear Medicine Department at the Uni-
versity Medical Centre. In vitro methods, except for
the assessment of internal dose performed by the
Institute of Occupational Safety, are not available
in Slovenia.
The legal framework in Slovenia has been already
updated. Slovenia adopted the Radiation Protection
and Nuclear Safety Act in 2002, which defines
two regulatory authorities. Besides the Slovenian
Nuclear Safety Administration a new regulatory
authority was established: the Slovenian Radiation
Protection Administration (SRPA). The SRPA is a
constituent part of the Ministry of Health, compe-
tent for the surveillance of radiation sources used in
medicine and veterinary, radiation protection of
exposed workers and population, medical surveil-
lance of exposed workers, education and training of
exposed workers in the field of radiation protection.
The updating process of the legislation is still going
on but the EU Directive 96/29 EURATOM has been
already fully transposed. Data on occupational per-
sonal doses are collected in the Central State Dose
Record at the SRPA. Regarding the internal expo-
sure only internal doses related to radon are included
at present.
Slovakia (Sk)
There are two institutes performing internal dosi-
metry in Slovakia. From them one is legally
approved internal dosimetry service in Slovakia,
associated to the Radiation Protection Department
Table 41. Internal dosimetric services in Hungary (HU) collaborating with Eurados.
Facility Exposure Direct techniques Indirect techniques
‘National Research Institute
for Radiobiology and
Radiohygiene
NPP, NFC, research, medical field,
public
WBC
KFKI Atomic Energy
Research Institute
Research reactor, radio chemistry,
isotope production, NPP, public
WBC, thyroid
monitoring
Gamma
Spectrometry, LSC
Table 42. Other internal dosimetric services in Hungary
(HU).
Country Facility
Hungary Institute of
Isotopes Co. Ltd
Nuclear Power
Station Paks
Table 43. Internal dosimetric services in Ireland (IE).
Facility Exposure Direct
techniques
Indirect
techniques
St Vincent’s
University
Hospital
Research, medical
field, non-nuclear
industry
WBC Urine samples
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of Bohunice Nuclear Power Plant (Table 56). Workers
are in vivo monitored in WBC and thyroid counting
(131I) geometries. In vitro techniques applied in the
service are LSC for beta emitters in urine and gamma
spectrometry for urine and faeces; Pu isotopes assess-
ment in faeces after radiochemical separation is also
considered.
The second institute (no need of legal approval yet)
is associated with the Department of Radiation
Hygiene of Research base of Slovak Medical Univer-
sity, Institute of Preventive and Clinical Medicine,
Bratislava. Monitored workers develop tasks in two
different facilities: the Cyclotron Centre of Slovak
Republic and Nuclear Medicine Department at the
Oncological Institute of St Elizabeth, Bratislava. Occu-
pational exposures are evaluated applying direct tech-
niques (WBC, lung counting and thyroid counting).
Intakes produced in research and medical facilities are
calculated using WBC results as in vivo technique.
Ukraine (Ua)
The WBC laboratory at the Research Centre for
Radiation Medicine AMS collaborated with
Table 44. Internal dosimetric services in Italy (IT) collaborating with Eurados.
Facility Exposure Direct techniques Indirect techniques
Ospedale Niguarda
Ca’Granda-Servizio
di Fisica Sanitaria
Medical field Thyroid counting Gamma spectroscopy,
LSC
ISPRA–Radiological
Protection Unit
NPP, research WBC, lung counting —
SOGIN–Societa Gestione
Impianti Nucleari–NPP
Enrico Fermi
NPP, decommissioning WBC —
SOGIN–Caorso NPP Health
Physics Department
Decommissioning,
non-nuculear industry
WBC, lung counting,
thyroid counting, GI
counting
—
ARPA Piemonte–
Dipartimento di Ivrea
— —
Bufalini Hospital–Health and
Medical Physic Department
Medical field — Gamma spectrometry
(urine); air filters
Lab. Servizio Fisica Sanitaria
Policlinico University Agostino
Gemelli
Medical field Thyroid counting Spectrometry (urine)
ENEA Research, decommissioning,
medical field,
non-nuclear industry,
others (waste
management, medicine)
WBC, lung counting,
thyroid counting,
bone (head) counting
Urine: gamma and alpha
spectrometry, LSC, beta
counting, fluorimetry
Faeces: alpha
spectrometry
Dose assessment
Table 45. Other internal dosimetric services in Italy (IT).
Country Facility
Italy ‘S.Maria della Misericordia’ Hospital, Health Physic Department, Udine
Varese Hospital, Health Physic Department, Varese
‘Casa Sollievo della Sofferenza’ Hospital, Health Physic Department,
S. Giovanni Rotondo (FG)
Galliera hospital, Health Physic Department, Genova
‘Istituti Ospitalieri’ Hospital, Health Physic Department, Cremona
Maggiore Hospital, Health Physic Department, Bologna
Latina NPP, SOGIN, Borgo Sabotino (LT)
Garigliano NPP, SOGIN, Scauri (LT)
Saluggia Research Center, ENEA, Saluggia (VC)
Trisaia Research Center, ENEA, Rotondella (MT)
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Eurados, supplying information about in vivo
evaluation of internal exposures in the Ukraine
(Table 57).
Other European countries
Eurados contacted the Latvian Radiation Safety
Centre. Although no replies were received, the
contact-person indicated that there are two internal
dosimetric services operating in Latvia (Table 58).
There is no legal requirement for the approval of
internal dosimetric services. Both services are oper-
ating in medical field, performing in vivo measure-
ment of 99Tcm and 131I. In Finland, STUK is the
only centre performing Internal Dosimetry.
INTEGRATION OF DOSIMETRIC DATA
In radiation protection dosimetry, the quantity of
interest for application of the dose limitation legal
requirements is the effective dose (E ), defined by the
expression:
E ¼
X
T
wTHT ¼
X
T
wT
X
R
wRDT,R
where DT,R is the absorbed dose averaged over tissue
or organ T, due to radiation R, wR is the radiation
weighting factor and wT is the tissue weighting factor
for tissue or organ T.
The radiation and tissue weighting factor are spe-
cified in the ICRP Publication 60.
The limit on effective dose to an adult worker
applies to the sum of the relevant effective doses
from external exposures during the appropriate
time period and the relevant committed effective
dose from intakes of radionuclides during that
period.
As DT,R is a quantity not directly measurable, in
external dosimetry the operational quantities
personal dose equivalent, HP(d ), and ambient dose
equivalent, H (10), are defined (ICRU Report 39,
1985)(14,15) to provide, under appropriate condi-
tions, an adequate and conservative estimate of
Table 46. Internal dosimetric services in Lithuania (LT).
Facility Exposure Direct techniques Indirect techniques
Ignalina Nuclear
Power Plant
NPP WBC —
Radiation
Protection Centre
NPP, research, decommissioning,
medical field, non-nuclear
industry, others
— Alpha, beta and gamma
spectrometry, gross beta
counting, SAS
Table 47. Internal dosimetric services in Netherlands (NL).
Facility Exposure Direct
techniques
Indirect
techniques
NRG
Radiation and
Environment
NPP, non-nuclear
industry, visits
WBC LSC
Table 48. Internal dosimetric services in Norway (NO)
collaborating with Eurados.
Facility Exposure Direct
techniques
Indirect
techniques
Institutt for
energiteknikk,
IFE, Halden
Research WBC, thyroid
detector
Urine samples
Table 49. Other internal dosimetric services in Norway
(NO).
Country Facility
Norway Norwegan Radiation Protection Authority
Institutt for energiteknikk–IFE, Kjeller
Table 50. Internal dosimetric services in Poland (PL).
Facility Exposure Direct
techniques
Indirect
techniques
Central Laboratory
for Radiological
Protection
Medical
field
Thyroid
counting
—
Table 51. Internal dosimetric services in Portugal (PT).
Facility Exposure Direct
techniques
Indirect
techniques
ITN-DPRSN Medical field,
research
WBC —
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effective dose for the most commonly encountered
external ionising radiation fields.
Internal doses cannot be measured directly, they
can only be inferred from measured quantities such
as body content, excretion rates or airborne concen-
trations of radioactive material. The choice of meas-
urement technique will be determined by several
factors: radiation emitted by the radionuclide, the
biokinetic behaviour of the contaminant, its reten-
tion in the body taking into account both biological
clearance and radioactive decay; the frequency of
measurements and the sensitivity, availability
and convenience of the appropriate measurement
techniques.
ICRP has developed a set of models to repre-
sent the behaviour of radionuclides that have
entered the body either by inhalation or by inges-
tion; these biokinetic models are applied for the
evaluation of the doses from measurements per-
formed according to routine monitoring pro-
grammes. The estimation of doses in case of an
accident needs more specific information about the
time and pattern of intake, about the physico-
chemical form of the radionuclides and the char-
acteristics of the individual.
Individual monitoring for estimation of internal
exposures may include either direct measurements of
radionuclide in the body and/or measurement of
activity in excreta. Any measurement should enable
each radionuclide to be identified, its activity quan-
tified, and the measurement result interpreted in
terms of intake or committed effective dose. Alter-
natively, measurements of activity in the body can be
used to estimate dose rates directly; the calculation
of committed doses from direct measurements still
involves the assumption of a biokinetic model if
sufficient measurements are not available to deter-
mine retention functions.
Integration of dosimetric methods for external
and internal radiations will be possible where
complete characterisation of the type of occupa-
tional exposure present in the workplace has been
undertaken; updated information about the
Table 52. Internal dosimetric services in Romania (RO).
Facility Exposure Direct techniques Indirect techniques
Institute of Public Health,
Bucharest Group I,
Radiochemistry
Research, public after
Chernobyl
— Radiochemical separation
of Sr in urine
Institute of Public Health,
Bucharest Group II, Gamma
Spectroscopy
Research, medical field,
137Cs in public
(after Chernobyl)
— Spectrometry for urine
Radiobiology Centre, Fundeni
Clinical Hospital Radiobiology
Others — Spectrometry for urine
Department
Internal Contamination
Monitoring Laboratory
Research, medical field WBC, thyroid counting —
CNE-PROD CERNAVODA-
Health Physics Laboratory
NPP WBC routine 3H and 14C routine; gamma
spectrometry (investigation)
Table 53. Internal dosimetric services in Sweden (SE) collaborating with Eurados.
Facility Exposure Direct techniques Indirect techniques
OKG Aktiebolag NPP WBC Gamma spectrometry
Studsvik Nuclear NPP, NFC, research,
decommissioning, medical field
WBC, thyroid counting Spectrometry for urine and faeces,
ICP-MS, environmental dosimetry
Radiation Physics,
Ringals NPP
NPP WBC, Quick Scan Spectrometry
Table 54. Other internal dosimetric services in Sweden (SE).
Country Facility
Sweden Westinghouse Atom AB
Barseba¨ck Kraft AB, NPP
Forsmarks Kraftgrupp AB, NPP
The Swedish Defence Research Agency, FOI
Radiophysics, Gothenburg, Medical field
Radiophysics, Malmo¨, Medical field
Radiophysics, Umea˚, Medical field
Swedish Radiation Protection Authority, SSI
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actual risk of contamination of workers is
required, with a knowledge of radiation fields
and of physicochemical characteristics of the
radioactive materials present in the workplace. In
this case, the committed effective dose associated
with the intake obtained from the results of direct
and/or indirect measurements, applying adequate
individual monitoring programmes of the exposed
workers, will be integrated to external doses in a
consistent dosimetric system, where both types of
exposures are considered.
Table 55. Internal dosimetric services in Slovenia (SI).
Facility Exposure Direct techniques Indirect techniques
Krsko NPP, Radiation Protection
Dosimetry Laboratory
NPP WBC, lung counting
thyroid counting
—
University Medical Centre,
Department of Nuclear Medicine
Research, medical field,
non-nuclear industry
WBC —
Institute of Occupational Safety — — 
See Table 18.
Table 56. Internal dosimetric services in Slovakia (SK).
Facility Exposure Direct techniques Indirect techniques
Radiation Protection Department,
Bohunice NPP
NPP, research,
decommissioning
Fastscan, WBC, 131I in
thyroid
LSC (urine), gamma spectrometry
(urine and faeces), Pu isotopes
assessment after radiochemical
separation (faeces)
Department of Radiation Hygiene
of Research base of Slovak
Medical University, Institute of
Preventive and Clinical Medicine
Radiopharmaceutical
production, research
WBC —
Table 57. Internal dosimetric services in Ukraine (UA).
Facility Exposure Direct
techniques
Indirect
techniques
WBC-laboratory
of Research
Centre for
Radiation Medicine
AMS Ukraine
NPP WBC, lung
counting,
beta in vivo
counting
—
Table 58. Internal dosimetric services in Latvia (LV).
Country Facility
Latvia P. Stradin Clinical Hospital
Latvian Oncology Centre
Table 59. Countries and contact persons collaborating with
Eurados.
Code Country Contact-Person
AT Austria Alexander Brandl
BE Belgium Christian Hurtgen
BG Bulgaria Metody Guelev
CH Switzerland Christian Wernli
CS Serbia and
Montenegro
Mirjana Prokic
CZ Czech Republic Karla Petrova
DE Germany Andreas Dalheimer
DK Denmark Rolf Falk
EE Estonia Toomas Koop
ES Spain Maria Antonia Lopez
GB United Kingdom George Etherington
GR Greece Vassiliki Kamenopoulu
HR Croatia Maria Ragonajec
HU Hungary Andor Andrasi/
Marika Osvay
IE Ireland Lorraine Currivan
IT Italy Carlo M Castellani
LT Lithuania Gendrutis Morkunas
NL The Netherlands Janwillem van Dijk
NO Norway Rolf Falk
PL Poland Pawel Olko
PT Portugal Joao Alves
RO Romania Constantin Milu
SE Sweden Rolf Falk
SI Slovenia Helena Janzejovic
SK Slovakia Nikodemova Denisa
UA Ukraine Vadim Chumak
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CONCLUSIONS
The final objective of EURADOS working group 2 is
to achieve the harmonisation in individual monitor-
ing for occupational exposures. Subgroup 2 looked
at the integration of monitoring for external and
internal exposures in the assessment of Effective
Doses. An important network of information has
been established among 26 European countries with
the assistance of contact persons who have actively
collaborated with EURADOS in the distribution of
Questionnaires among their internal dosimetry facil-
ities. An extensive amount of information was col-
lected from some 73 services, covering a wide range
of parameters, for example equipment, techniques,
tools and regulations. This results in an overview of
the actual status of individual monitoring for inter-
nal exposures in Europe. Harmonisation is a reality
in many aspects of internal dose assessments, espe-
cially when considering the measurements of the
activity retained/excreted from the body. However,
a future study, detailing MDA estimation is highly
recommended. Points which should be focused on in
future harmonisation projects are as follows: the
process of calculation of doses from measured activ-
ity, establishment of guidelines, similar dosimetric
tools and application of the same ICRP recommen-
dations. This would lead to a better and more har-
monised approach to the estimation of internal
exposures in all European facilities.
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ANNEX
Table AN1. List of internal dosimetric services collaborating with Eurados.
AT ARCS Seibersdorf Research GmbH (Alexander Brandl) Seibersdorf, Austria. E-mail: alexander.
brandl@arcs.ac.at
AT Pru¨fstelle fu¨r Strahlenschutz, Landeskrankenhaus-Universita¨tsklinikum Graz (Ewald Plantosar), Austria.
E-mail: strahlenschutz@klinikum-graz.at
BE SCK-CEN (Christian Hurtgen), Mol, Belgium. E-mail: churtgen@sckcen.be
BG Kozloduy Nuclear Power Plant (Maria Neshkova), Kozloduy, Bulgaria. E-mail: mneshkova@npp.cit.bg
CH PSI–Paul Scherrer Institute (Christian Wernli), Villigen-PSI. E-mail: christian.wernli@psi.ch
CH Institut Universitaire de Radiophysique Applique´e (Sebastien Baechler), Lausanne, Switzerland. E-mail:
Andre.Besancon@inst.hospvd.ch
CH BKW FMB Energie AG (Peter Strebel), Muhleberg, Switzerland. E-mail: markus.zuercher@bkw-fmb.ch
CH RC Tritec Ltd (E. Bannwart), Teufen, Switzerland. E-mail: bannwart@rctritec.com
CH Suva–Swiss National Accident Insurance Fund (M. Hammans), Luzern, Niederwangen, Switzerland. E-mail:
michel.hammans@suva.ch
CH mb-microtec ag (Jakob Banziger), Switzerland. E-mail: jb@mbmicrotec.com; ss@microtec.com
CH Whole Body Counter University Hospital Basel (Hans W. Roser), Basel, Switzerland. E-mail:
hroser@uhbs.ch
CS Institute of Occupational Health (Gordana Pantelic), Belgrade, Serbia and Montenegro. E-mail:
Dpantelic@ptt.yu
CS Institute of Nuclear Sciences Vinca (V Spasojevic/S Pavlovic), Belgrade, Serbia and Montenegro. E-mail:
keneski@rt270.vin.bg.ac.yu
CZ National Radiation Protection Institute (Petr Rulik/Vera Beckova), Prague, Czech Republic. E-mail:
prulik@suro.cz; vbeckova@suro.cz
CZ Personal Dosimetry Service-Temelin NPP (Milan Tomasek), Czech Republic. E-mail:
tomasml.ete@mail.cez.cz
CZ Nuclear Research Institute Rez (Milos Vidra), Czech Republic. E-mail: VID@NRI.CZ
CZ Dukovany Nuclear Power Plant (Bozena Jurochova), Dukovany, Czech Republic. E-mail:
jurocb1.edu@mail.cez.cz
DE Universita¨tsklinikum Essen-Klinik fuer Nuklearmedizin (Wilfried Sonnenschein), Essen, Germany. E-mail:
w.sonnenschein@uni-essen.de
DE A.K. St Georg Abteilung fu¨r Nuklearmedizin (Bernhard Leisner), Hamburg, Germany. E-mail:
nuklearmedizin.akstgeorg@t-online.de
DE Landesanstalt fu¨r Umweltschutz Baden-Wuerttemberg (Susanne Weimer), Karlsruhe, Germany. E-mail:
Susanne.Weimer@lfuka.lfu.bwl.de
DE Bundesamt fu¨r Strahlenschutz—BfS (Karin Dettman), Berlin, Germany. E-mail: kdettmann@bfs.de
DE Framatome ANP GmbH (Nikolaus Neudert), Erlangen, Germany. E-mail: Nikolaus.Neudert@framatome-
anp.com
DE Siemens AG, Power Generation (Gerhard Fischbach), DP Hanau, Germany. E-mail:
Gerhard.Fischbach@Siemens.com
DE Amtlich anerkannte Inkorporationsmesstelle im Forschungszentrum Ju¨lich (Peter Hill/M. Schlaeger),
Germany. E-mail: p.hill@fz-juelich.de, m.schlaeger@fz-juelich.de
DE Forschungszentrum Karlsruhe Technik und Umwelt (Hans Doerfel), Eggenstein-Leopoldshafen, Germany.
E-mail: Hans.Doerfel@hs.fzk.de
DK Applied Health Physics, Riso National Laboratory (Bente Lauridsen), Roskilde, Denmark. E-mail:
bente.lauridsen@risoe.dk
EE AS Ecosil (Dina Shestakova), Sillama¨e, Estonia. E-mail: shestakova@as.silmet.ee
ES CIEMAT–Centro de Investigaciones Energeticas Medioambientales y Tecnologicas (Teresa Navarro),
Madrid, Spain. E-mail: teresa.navarro@ciemat.es
ES ENUSA (Agustı´n Pe´rez Fonseca), Juzbado-Salamanca, Spain. E-mail: apf@fab.enusa.es
ES TECNATOM-Servicio de Dosimetrı´a (Paloma Marchena), Madrid, Spain. E-mail: pmarchena@tecnatom.es
ES Central Nuclear Asco (Francisco G.Tardiu), Asco-Tarragona, Spain. E-mail: fgtardiu@anacnv.com
ES Central Nuclear Vandellos II (Juan Manuel Gamo), L’Hospitalet de L’Infant, Spain. E-mail:
jmgamo@anacnv.com
ES Central Nuclear Trillo (Jose´ Antonio Prieto), Trillo-Guadalajara, Spain. E-mail: Ja.prieto@cnat.es
ES Central Nuclear Almaraz (Domingo Sustacha), Navalmoral de la Mata, Spain. E-mail: dsd@cnat.es
ES Central Nuclear Jose Cabrera–Zorita (Lorenzo Revuelta), Almonacid de Zorita, Spain. E-mail:
Lrevueltag@uef.es
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Table AN1. Continued.
ES Central Nuclear Cofrentes (Eduardo Sollet), Cofrentes, Spain. E-mail: Eduardo.Sollet@iberdrola.es
GB Rolls Royce Marine Operations Limited (Barry Cripwell), Derby, United Kingdom. E-mail:
Lesley.Hales@Rolls-Royce.com
GB AWE plc /Harwell Scientifics (Rupert Cockerill), England, United Kingdom. E-mail:
Rupert.Cockerill@awe.co.uk
GB RWE NUKEM Ltd/Harwell laboratories (Gareth Roberts), United Kingdom. E-mail:
Richard.Birch@rwenukem.co.uk
GR Greek Atomic Energy Commission–Department of Environment Radioactivity (Virginia Koukouliou), Agia
Paraskevi, Greece. E-mail: vkoukoul@eeae.nrcps.ariadne-t.gr
GR Ioannina University Medical Physics Laboratory (John A. Kalef-Ezra), Ioannina, Greece. E-mail:
Jkalef@ccuoi.gr
HR Department of Nuclear Medicine and Radiation Protection (Mario Medvedec/M.Uvi), Zagreb, Croatia.
E-mail: kmira@kbc-zagreb.hr
HU National Research Institute for Radiobiology and Radiohygiene (A. Kerekes), Budapest, Hungary. E-mail:
kerekes@hp.osski.hu
HU KFKI Atomic Energy Research Institute (L. Sagi), Budapest, Hungary. E-mail: sagi@sunserv.kfki.hu
IE St Vincent’s University Hospital (Michael Casey), Dublin, Ireland. E-mail: m.casey@st-vincents.ie
IT Ospedale Niguarda Ca’Granda-Servizio di Fisica Sanitaria (Marco Minella), Milano, Italy. E-mail:
sfsnig@mailserver.unimi.it
IT ISPRA–Radiological Protection Unit (Emilio Ribolzi), Varese, Italy. E-mail: emilio.ribolzi@cec.eu.int.it
IT SOGIN–Societa Gestione Impianti Nucleari-NPP E.Fermi (Davide Galli), Trino, Italy. E-mail:
galli@sogin.it; galli.davide@enel.it
IT SOGIN–Caorso NPP Health Physics Department (Roberto Bellintani), Caorso/Piacenza, Italy. E-mail:
Bellintani.roberto@enel.it
IT ARPA Piemonte–Dipartimento di Ivrea (Maria Clivia Losana), Ivrea (TO), Italy. E-mail:
m.losana@arpa.piemonte.it
IT Bufalini Hospital–Health and Medical Physic Department (Lazzari Simonetta), Cesena, Italy, E-mail:
fis.san@ausl.cesena.emr.it
IT Lab. Servizio Fisica Sanitaria Policlinico Univ. Agostino Gemelli (Fabrizio Cichoki), Roma, Italy. E-mail:
radioprotezione@rm.unicatt.it
IT ENEA (Paolo Battisti), Sta Maria di Galeria (Roma), Italy, E-mail: nadia.dimarco@casaccia.enea.it;
giachetti.achille@casaccia.enea.it
LT Ignalina Nuclear Power Plant (Victor Pletniov), Visaginas, Italy. E-mail: pletnev@mail.iae.lt
LT Radiation Protection Centre (Gendrutis Morkunas), Vilnius, Lithuania. E-mail: genmo@takas.lt
NL NRG Radiation and Environment (W. Van Dijk), Arnhem, The Netherlands. E-mail: jw.vandijk@
nrg-nl.com
NO Institutt for energiteknikk, IFE (Heidi Andersen), Halden, Norway. E-mail: heidia@hrp.no
PL Central Laboratory for Radiological Protection (G. Krajewska), Warsaw, Poland. E-mail:
krajewski@clor.waw.pl
PT ITN-DPRSN (A.D. Oliveira), Lisbon, Portugal. E-mail: jgalves@itn.pt
RO Institute of Public Health-Group I–Radiochemistry (Toader M), Bucharest, Romania. E-mail: cmilu@ispb.ro
RO Institute of Public Health-Group II–Gamma Spectroscopy (Gheorghe R), Bucharest, Romania. E-mail:
cmilu@ispb.ro
RO Radiobiology Centre–Fundeni Clinical Hospital Radiobiology Department, Bucharest, Romania. E-mail:
cmilu@ispb.ro
RO Internal Contamination Monitoring Laboratory (Mirela Angela Puscalau), Bucharest-Magurele, Romania.
E-mail: puscalau@ifin.nipne.ro
RO CNE-PROD CERNAVODA–Health Physics Laboratory (Mitica Baraitaru), Cernavoda, Romania. E-mail:
mbaraitaru@cne.ro
SE OKG Aktiebolag (Mats Hjelm), Oskarshamn, Sweden. E-mail: mats.hjelm@okg.sydkraft.se
SE Studsvik Nuclear (Nils Addo), Nyko¨ping, Studsvik, Sweden. E-mail: nils.addo@studsvik.se
SE Radiation Physics, Ringals NPP (Annette Lo¨vefors), Va¨ro¨backa, Sweden. E-mail: Annette.lovefors-
daun@ringhals.se
SI Institute of Occupational Safety (Peter Jovanovic), Ljubljana, Slovenia. E-mail: Peter.jovanovic@zvd.si
SI University Medical Centre–Department of Nuclear Medicine (Marko Grmek), Ljubljana, Slovenia. E-mail:
Marko.Grmek@kclj.si
SI Krsko NPP, Radiation Protection-Dosimetry Laboratory (Borut Breznik), Krsko, Slovenia. E-mail:
borut.breznik@nek.si
SK Radiation Protection Department, Bohunice NPP (Dobis Lubomir), Jaslovske Bohunice, Slovakia. E-mail:
dobis_lubomir@ebo.seas.sk
UA WBC–Lab. Research Centre for Radiation Medicine AMS (O.N. Perevoznikov), Kiev, Ukraine. E-mail:
Sichlab@i.com.ua
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APPENDIX
Table AP1. Facilities included in the EURADOS Dosimetric Database (v 1.0).
Country Ref-Facility Facility
AT At-GR Pru¨fstelle fu¨r Strahlenschutz, Landeskrankenhaus-Universita¨tsklinikum Graz
At-AR ARCS Seibersdorf Research GmbH
BE Be-SC SCK–CEN
BG Bg-KL Laboratory of Dosimetry and Radiation Protection, St Kliment Ohridski University of Sofia
Bg-KO Kozloduy Nuclear Power Plant-PLC
Bg-NR Institute for Nuclear Research and Nuclear Energy
Bg-PR Laboratories Protecta Ltd
Bg-RB Nat Centre of Radiobiology and Radiation Protection Laboratory
Bg-RW Radioactive Wastes Treatment Plant (RAWTP)-Kozloduy NPP
CH Ch-BA Whole Body Counter University Hospital Basel
Ch-BK BKW FMB Energie AG
Ch-MB mb-microtec ag
Ch-PS PSI–Paul Scherrer Institute
Ch-RA Institut Universitaire de Radiophysique Applique´e
Ch-RC RC Tritec Ltd
Ch-SU Suva (Swiss National Accident Insurance Fund)
CS Cs-NS Institute of Nuclear Sciences, Vinca
Cs-OS Institute of Occupational Health, Belgrade
CZ Cz-DU Dukovany Nuclear Power Plant
Cz-NP National Personnel Dosimetry Service
Cz-NR Nuclear Research Institute, Rez
Cz-RP National Radiation Protection Institute
Cz-TE Personal Dosimetry Service–Temelin NPP
DE De-BS Bundesamt fu¨r Strahlenschutz (BfS)
De-DO Materialpru¨fungsamt NRW (MPA NRW), Personendosismesstelle
De-FJ Amtlich anerkannte Inkorporationsmessstelle im, Forschungszentrum, Ju¨lich
De-FR Framatome ANP GmbH
De-GA A.K. St Georg Abteilung fu¨r Nuklearmedizin
De-KT Forschungszentrum Karlsruhe Technik und Umwelt
De-LU Landesanstalt fu¨er Umweltschutz Baden-Wuerttemberg
De-MS Messtelle fu¨r Strahlenschutz, Hamburg
De-SH Siemens AG, Power Generation, DP Hanau
De-UE Universita¨tsklinikum Essen
DK Dk-RH National Institute of Radiation Hygiene
Dk-RI Applied Health Physics, Riso National Laboratory
EE Ee-AS AS Ecosil
Ee-RP Estonian Radiation Protection Centre (ERPC)
Ee-TL TLD Group–ERPC
ES Es-AL Central Nuclear Almaraz
Es-AS Central Nuclear Asco
Es-CI CIEMAT
Es-CO Central Nuclear Cofrentes
Es-EN ENUSA
Es-TE TECNATOM
Es-TR Central Nuclear Trillo
Es-VA Central Nuclear Vandellos II
Es-ZO Central Nuclear Jose Cabrera (Zorita)
Es-GA Central Nuclear de Santa Marı´a de Garo~na
FI Fi-ST STUK- Radiation and Nuclear Safety Authority
GB Gb-AW AWE plc
Gb-RR Rolls Royce Marine Operations Limited
Gb-RW RWE NUKEM/Harwell Scientifics
GR Gr-AU Aristotle University of Thessaloniki, Polytechnic School, Laboratory of Nuclear Tech.
Gr-GA Greek Atomic Energy Commission–Department of Environment Radioactivity
Gr-IU Ioannina University Medical Physics Laboratory
HR Hr-BO Ru Er Boskovi Institute
Hr-EK EKOTEH Dosimetry Co. Radiation Protection Service
Hr-NM Department of Nuclear Medicine and Radiation Protection
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Table AP1. Continued.
Country Ref-Facility Facility
HU Hu-AE KFKI Atomic Energy Research Institute
Hu-RR National Research Institute for Radiobiology and Radiohygiene
IE Ie-RP Radiological Protection Institute of Ireland, Natural Radiation Department
Ie-SV St Vincent’s University Hospital
IT It-AG Lab Servizio Fisica Sanitaria del Policlinico Universitario Agostino Gemelli
It-AR ARPA Piemonte–Dipartimento di Ivrea
It-AS Fisica Sanitaria–ASL n.9 della Regione Veneto
It-BR Spedali Civili di Brescia–Servizio di Fisica Sanitaria
It-BU Bufalini Hospital–Health and Medical Physic Department
It-CA SOGIN–Caorso NPP Health Physics Department
It-CT Istituto Nazionale per lo studio e la cura dei Tumori
It-EF SOGIN–Societa Gestione Impianti Nucleari–NPP Enrico Fermi
It-EN ENEA
It-IS ISPRA–Radiological Protection Unit
It-MA Ospedale Maggiore–Servizio di Fisica Sanitaria
It-ON Ospedale Niguarda Ca’Granda–Servizio di Fisica Sanitaria
It-PE Azienda Ospedaliera di Perugia–Servizio di Fisica Sanitaria
It-RI ISPESL–Laboratorio Radiazioni Ionizzanti e Non Ionizzanti
It-RO C.I.R. (Centro Italiano di Radioprotezione Roma)
It-UM Umberto I Hospital–Medical Physics Department
It-XG X-GAMMAGUARD
LT Lt-IP Ignalina Nuclear Power Plant
Lt-RP Radiation Protection Centre
NL Nl-RE NRG Radiation and Environment
NO No-IE Institutt for energiteknikk, IFE
No-RP Norwegian radiation protection authority (NRPA)
PL Pl-GI Central Mining Institute (GIG)
Pl-IF Institute of Nuclear Physics–Laboratory of Individual and Environmental Dosmetry
Pl-NO Nofer Institute of Occupational Medicine-Radiation Protection Department
Pl-RP Central Laboratory for Radiological Protection
PT Pt-TN ITN-DPRSN
RO Ro-CL CIPIEM-Bucharest
Ro-CN CNE-PROD CERNAVODA–Health Physics Laboratory
Ro-DO DOZIMED–Bucharest
Ro-EL Environmental and Life Sciences Department
Ro-FD Film Detectors Survey Unit
Ro-HF Individual Radiation Monitoring Laboratory–Ministry of Health
Ro-IC Internal Contamination Monitoring Laboratory
Ro-PG Institute of Public Health Bucharest–Group II–Gamma spectroscopy
Ro-PR Institute of Public Health Bucharest–Group I–Radiochemistry
Ro-RB Radiobiology Centre–Bucharest
SE Se-HU Studsvik Nuclear
Se-OK OKG Aktiebolag
Se-RI Radiation Physics, Ringals NPP
Se-RP Swedish Radiation Protection Authority
SI Si-JS Jozˇef Stefan Institute
Si-KR Krsko NPP, Radiation Protection–Dosimetry Laboratory
Si-MC University Medical Centre, Department of Nuclear Medicine
Si-OS Institute of Occupational Safety
Si-UM Uranium Mine Zirovski vrh
SK Sk-BA Department of radiation hygiene of Research base of Slovak Medical University, Institute of
Preventive and Clinical Medicine
Sk-BO Radiation Protection Department, Bohunice NPP
Sk-RQ State Metrological Center for Radon Quantities
UA Ua-NR Laboratory for Hygiene of Natural Radiation sources, Research Centre Radiation Medicine
Ua-RM WBC–Laboratory Research Centre for Radiation Medicine AMS Ukraine
Ua-RP Radiation Protection Institute ATS Ukraine
Ua-SG Central Lab for rad hygiene of medical staff of Ukraine–S.Grigoriev Institute
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